{"id":12718,"date":"2026-02-17T18:46:40","date_gmt":"2026-02-17T18:46:40","guid":{"rendered":"https:\/\/csiag.eu\/?p=12718"},"modified":"2026-02-17T20:56:03","modified_gmt":"2026-02-17T20:56:03","slug":"ar-antivielam-saistita-slimiba-kas-saistita-ar-mogad","status":"publish","type":"post","link":"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/","title":{"rendered":"MOGAD - ar MOG antivielu saist\u012bta slim\u012bba"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_83 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Satura r\u0101d\u012bt\u0101js<\/p>\n<span class=\"ez-toc-title-toggle\"><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1' ><ul class='ez-toc-list-level-2' ><li class='ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Was_ist_MOGAD\" >Kas ir MOGAD?<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Was_geht_bei_MOGAD_schief\" >Kas notiek nepareizi MOGAD?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Wo_im_Korper_passiert_das\" >Kur organism\u0101 tas notiek?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Wie_verlauft_die_Erkrankung\" >K\u0101 slim\u012bba progres\u0113?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Wie_haufig_ist_MOGAD\" >Cik izplat\u012bts ir MOGAD?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Was_lost_MOGAD_aus\" >Kas izraisa MOGAD?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Wie_wird_MOGAD_behandelt\" >K\u0101 tiek \u0101rst\u0113ts MOGAD?<\/a><\/li><\/ul><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-1'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Wissenschaftliche_Einleitung_und_Definition\" >Zin\u0101tniskais ievads un defin\u012bcija<\/a><ul class='ez-toc-list-level-2' ><li class='ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Abgrenzung_von_MOGAD_NMOSD_und_MS\" >MOGAD, NMOSD un MS diferenci\u0101cija<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-1'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#MOG-Protein_%E2%80%93_Struktur_und_physiologische_Funktion\" >MOG prote\u012bns - strukt\u016bra un fiziolo\u0123isk\u0101 funkcija<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Strukturdomanen\" >Strukt\u016bras dom\u0113ni<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Physiologische_Funktionen\" >Fiziolo\u0123isk\u0101s funkcijas<\/a><\/li><\/ul><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-1'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Pathogenese_und_Immunpathologie\" >Pato\u0123en\u0113ze un im\u016bnpatolo\u0123ija<\/a><ul class='ez-toc-list-level-2' ><li class='ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Trigger_und_initiale_Aktivierung\" >Palaidnis un s\u0101kotn\u0113j\u0101 aktiviz\u0113\u0161ana<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#T-Zell-vermittelte_Pathogenese\" >T-\u0161\u016bnu medi\u0113t\u0101 pato\u0123en\u0113ze<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Phase_1_%E2%80%93_Periphere_Aktivierung\" >1. f\u0101ze - Perif\u0113risk\u0101 aktiviz\u0101cija<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Phase_2_%E2%80%93_BHS-Penetration\" >2. posms - BHS iespie\u0161an\u0101s<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Phase_3_%E2%80%93_Perivaskulare_Reaktivierung\" >3. f\u0101ze - Perivaskul\u0101ra reaktiv\u0101cija<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#B-Zell-_und_Antikorper-vermittelte_Pathogenese\" >B-\u0161\u016bnu un antivielu medi\u0113t\u0101 pato\u0123en\u0113ze<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-1'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Molekulare_Signalwege_und_Effektormechanismen\" >Molekul\u0101r\u0101s signaliz\u0101cijas ce\u013ci un iedarb\u012bbas meh\u0101nismi<\/a><ul class='ez-toc-list-level-2' ><li class='ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Signalweg_1_%E2%80%93_Klassischer_Komplementweg_CDC\" >Signaliz\u0101cijas ce\u013c\u0161 1 - klasiskais komplementa ce\u013c\u0161 (CDC)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Signalweg_2_%E2%80%93_Fc%CE%B3-Rezeptor-Weg_FcR-vermittelt\" >2. signaliz\u0101cijas ce\u013c\u0161 - Fc\u03b3 receptoru ce\u013c\u0161 (ar FcR starpniec\u012bbu)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Signalweg_3_%E2%80%93_IL-6JAK-STAT3-Weg\" >Signaliz\u0101cijas ce\u013c\u0161 3 - IL-6\/JAK-STAT3 ce\u013c\u0161<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Signalweg_4_%E2%80%93_MAPK-_und_AKT-Signalwege_B-Zellen\" >Signaliz\u0101cijas ce\u013c\u0161 4 - MAPK un AKT signaliz\u0101cijas ce\u013ci (B \u0161\u016bnas)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-25\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Signalweg_5_%E2%80%93_Th17-Zytokin-Netzwerk_im_ZNS\" >5. signaliz\u0101cijas ce\u013c\u0161 - Th17 citok\u012bnu t\u012bkls CNS<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-26\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Signalwege_%E2%80%93_Ubersicht\" >Signaliz\u0101cijas ce\u013ci - p\u0101rskats<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-1'><a class=\"ez-toc-link ez-toc-heading-27\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Relevante_Rezeptoren_und_Zielmolekule\" >Attiec\u012bgie receptori un m\u0113r\u0137a molekulas<\/a><ul class='ez-toc-list-level-2' ><li class='ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-28\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#MOG_selbst_als_Zielstruktur_kein_klassischer_Rezeptor\" >MOG k\u0101 m\u0113r\u0137a strukt\u016bra (nevis klasisks receptoru).<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-29\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Fc%CE%B3-Rezeptoren_Fc%CE%B3R\" >Fc\u03b3 receptori (Fc\u03b3R)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-30\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Neonataler_Fc-Rezeptor_FcRn\" >Jaundzimu\u0161o Fc receptori (FcRn)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-31\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#IL-6-Rezeptor_IL-6R%CE%B1_gp130\" >IL-6 receptoru (IL-6R\u03b1 \/ gp130)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-32\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#T-Zell-Rezeptor_TCR_und_Kostimulationsmolekule\" >T-\u0161\u016bnu receptoru (TCR) un kostimul\u0101cijas molekulas.<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-33\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Komplementrezeptoren\" >Komplementa receptori<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-1'><a class=\"ez-toc-link ez-toc-heading-34\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Histopathologie_und_ZNS-Lasionsmuster\" >Histopatolo\u0123ija un CNS boj\u0101jumu modelis<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-1'><a class=\"ez-toc-link ez-toc-heading-35\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Klinische_Manifestationen_und_Phanotypen\" >Kl\u012bnisk\u0101s izpausmes un fenotipi<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-1'><a class=\"ez-toc-link ez-toc-heading-36\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Diagnostik\" >Diagnostika<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-1'><a class=\"ez-toc-link ez-toc-heading-37\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Therapeutische_Strategien\" >Terapeitisk\u0101s strat\u0113\u0123ijas<\/a><ul class='ez-toc-list-level-2' ><li class='ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-38\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Akuttherapie_Schubbehandlung\" >Ak\u016bta terapija (recid\u012bva \u0101rst\u0113\u0161ana)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-39\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Prophylaktische_Langzeittherapie\" >Profilaktiska ilgtermi\u0146a terapija<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-40\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Klinische_Studien_%E2%80%93_2024%E2%80%932026\" >Kl\u012bniskie p\u0113t\u012bjumi - 2024-2026<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-41\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Neue_und_zukunftige_Therapiekonzepte\" >Jaunas un n\u0101kotnes terapijas koncepcijas<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-42\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#BTK-Inhibitoren_Bruton-Tyrosin-Kinase\" >BTK inhibitori (Brutona tiroz\u012bnkin\u0101ze)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-43\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Toleranzinduktion_MOG-Tolerisierung\" >Tolerances izrais\u012b\u0161ana (MOG toler\u0113\u0161ana)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-44\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Komplementinhibitoren\" >Komplementa inhibitori<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-45\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Anti-Neonatal-Fc-Rezeptor-Strategien\" >Strat\u0113\u0123ijas pret neonat\u0101lo Fc receptoru<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-46\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Autologe_hamatopoetische_Stammzelltransplantation_aHSCT\" >Autolog\u0101 hematopo\u0113tisko cilmes \u0161\u016bnu transplant\u0101cija (aHSCT)<\/a><\/li><\/ul><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-1'><a class=\"ez-toc-link ez-toc-heading-47\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Biomarker_und_Verlaufsmonitoring\" >Biomar\u0137ieri un turpm\u0101k\u0101 uzraudz\u012bba<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-1'><a class=\"ez-toc-link ez-toc-heading-48\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Prognose_und_Besonderheiten\" >Prognozes un \u012bpa\u0161as funkcijas<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-1'><a class=\"ez-toc-link ez-toc-heading-49\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Zusammenfassung_und_Ausblick\" >Kopsavilkums un perspekt\u012bvas<\/a><ul class='ez-toc-list-level-2' ><li class='ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-50\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Atherischer_Ole_%E2%80%93_Wirkstoffe_nach_Signalwegen_geordnet\" >\u0112terisk\u0101s e\u013c\u013cas - akt\u012bv\u0101s sast\u0101vda\u013cas, kas sak\u0101rtotas p\u0113c signaliz\u0101cijas ce\u013ciem<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-51\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Weihrauch_Boswellia_serrata_%E2%80%93_AKBA_und_Incensolacetat\" >Frankincense (Boswellia serrata) - AKBA un incensola acet\u0101ts<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-52\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Therapeutisch_relevante_AKBA-Zieldosen\" >Terapeitiski atbilsto\u0161as AKBA m\u0113r\u0137a devas<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-53\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Umrechnung_auf_375_mg_AKBA_jeKapsel\" >Konvert\u0113t uz 37,5 mg AKBA vien\u0101 kapsul\u0101<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-54\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Wichtige_Einnahmehinweise\" >Svar\u012bgi uz\u0146em\u0161anas nor\u0101d\u012bjumi<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-55\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Schwarzer_Pfeffer_oral\" >Melnie pipari (iek\u0161\u0137\u012bgi)<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-56\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Schwarzer_Pfeffer_Inhalation\" >Melnie pipari (inhal\u0101cijai)<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-57\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Copaiba-Ol_oral_%E2%80%93_NUR_doTERRA\" >Copaiba e\u013c\u013ca (iek\u0161\u0137\u012bgi) - TIKAI doTERRA<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-58\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#MOGAD-spezifische_Dosierungstabelle_doTERRA_Copaiba_525_BCP\" >MOGAD specifiska doz\u0113\u0161anas tabula (doTERRA Copaiba 52,5 % BCP)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-59\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#MOGAD-Phasen-adaptierte_Dosierung\" >MOGAD f\u0101z\u0113m piel\u0101gota doz\u0113\u0161ana<\/a><ul class='ez-toc-list-level-4' ><li class='ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-60\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Phase_1_Akuter_Schub_erste_2%E2%80%934_Wochen\" >1. f\u0101ze: ak\u016bts paasin\u0101jums (pirm\u0101s 2-4 ned\u0113\u013cas)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-61\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Phase_2_Schubremission_Erhaltung_langfristig\" >2. f\u0101ze: recid\u012bva remisija \/ uztur\u0113\u0161ana (ilgtermi\u0146a)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-62\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Phase_3_Monophasischer_Verlauf_Titer_fallend\" >3. f\u0101ze: monof\u0101zisks kurss (titra samazin\u0101\u0161an\u0101s)<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-63\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Quellen\" >Avoti<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-64\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Copaiba-Ol_Inhalation\" >Kopaibas e\u013c\u013ca (inhal\u0101cijai)<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-65\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Zieldosen_und_benotigte_Tropfenzahl\" >M\u0113r\u0137a devas un nepiecie\u0161amais pilienu skaits<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-66\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Synergistische_MOGAD-Strategie_Multi-Target\" >Siner\u0123iska MOGAD strat\u0113\u0123ija (vair\u0101ku m\u0113r\u0137u)<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-67\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Wichtige_MOGAD-spezifische_Hinweise\" >Svar\u012bga MOGAD specifiska inform\u0101cija<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-68\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#%CE%B1-Asaron_Kalmus-Ol_Acorus_calamus_%E2%80%93_direkt_oligodendrozytenprotektiv\" >\u03b1-Asarons (kalmju e\u013c\u013ca, Acorus calamus) - tie\u0161i oligodendroc\u012btus aizsarg\u0101jo\u0161s l\u012bdzeklis<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-69\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Geraniumol_Pelargonium_graveolens_%E2%80%93_Neuroinflammation_und_NO\" >Pelargoniju e\u013c\u013ca (Pelargonium graveolens) - neiroinflammation un NO<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-70\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Teebaum-Ol_Melaleuca_alternifolia_%E2%80%93_Mikroglia-Modulation\" >T\u0113jas koka e\u013c\u013ca (Melaleuca alternifolia) - mikroglijas modul\u0101cija<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-71\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Wirkstoffubersicht_nach_MOGAD-Signalwegen\" >Akt\u012bvo vielu p\u0101rskats saska\u0146\u0101 ar MOGAD signaliz\u0101cijas ce\u013ciem<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-72\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Quellen_und_weiterfuhrende_Literatur\" >Avoti un turpm\u0101k\u0101 las\u0101mviela<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<span class=\"span-reading-time rt-reading-time\" style=\"display: block;\"><span class=\"rt-label rt-prefix\">Las\u012b\u0161anas laiks<\/span> <span class=\"rt-time\"> 17<\/span> <span class=\"rt-label rt-postfix\">protokols<\/span><\/span>\n<p><em>Miel\u012bna oligodendroc\u012btu glikoprote\u012bna antivielu saist\u012bt\u0101 slim\u012bba<\/em><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Was_ist_MOGAD\"><\/span>Kas ir MOGAD?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Ikviens zina elektr\u012bbas kabe\u013cus: Tie ir apr\u012bkoti ar izol\u0101ciju, kas atdala atsevi\u0161\u0137us kabe\u013cu k\u016b\u013ca k\u016b\u013ca vadus vienu no otra, lai sign\u0101li tajos netrauc\u0113tu viens otram un netrauc\u0113ti nok\u013c\u016btu no punkta A uz punktu B.<br>Muguras smadzen\u0113s ir vesela virkne \u0161\u0101du kabe\u013cu sai\u0161\u0137u. Tie vada nervu sign\u0101lus no galvas smadzen\u0113m uz da\u017e\u0101diem \u0137erme\u0146a org\u0101niem, musku\u013ciem, audiem utt. Kam\u0113r kabe\u013ca izol\u0101cija ir izgatavota no plastmasas, tekstilmateri\u0101liem vai \u012bpa\u0161iem materi\u0101liem, muguras smadze\u0146u izol\u0101cijas sl\u0101nis ir izgatavots no \u012bpa\u0161a materi\u0101la. <strong>Miel\u012bna sl\u0101nis<\/strong>.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Was_geht_bei_MOGAD_schief\"><\/span>Kas notiek nepareizi MOGAD?<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>MOGAD gad\u012bjum\u0101 organisma im\u016bnsist\u0113ma pie\u013cauj nopietnu k\u013c\u016bdu: t\u0101 k\u013c\u016bdaini ra\u017eo. <strong>Antivielas pret specifisku olbaltumvielu, kas atrodas \u0161\u012b izol\u0113jo\u0161\u0101 sl\u0101\u0146a \u0101rpus\u0113.<\/strong>, t\u0101 saukto. <strong>MOG<\/strong>-prote\u012bns. Antivielas faktiski ir organisma sargsu\u0146i, kas atpaz\u012bst, iez\u012bm\u0113 un izn\u012bcina patog\u0113nus, piem\u0113ram, v\u012brusus un bakt\u0113rijas. Tom\u0113r MOGAD gad\u012bjum\u0101 t\u0101s ir k\u013c\u016bdaini v\u0113rstas pret pa\u0161a organisma veseliem audiem - nervu \u0161\u0137iedru izol\u0101ciju.<\/p>\n\n\n\n<p>Sal\u012bdzinot ar kabeli, tas ir t\u0101pat k\u0101 skr\u0101p\u0113jumi, nobr\u0101zumi vai korozija, kas izraisa izol\u0101cijas perfor\u0101ciju, un elektriskie sign\u0101li vairs nesasniedz savu galam\u0113r\u0137i t\u012bri vai pat visp\u0101r nesasniedz.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Wo_im_Korper_passiert_das\"><\/span>Kur organism\u0101 tas notiek?<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>MOGAD attiecas tikai uz <strong>Centr\u0101l\u0101 nervu sist\u0113ma<\/strong>, t. i., galvas un muguras smadzenes, muguras smadzenes un redzes nervus. Atkar\u012bb\u0101 no skart\u0101s zonas rodas da\u017e\u0101di simptomi:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Redzes nervs<\/strong> - P\u0113k\u0161\u0146s redzes zudums, redzes miglo\u0161an\u0101s, s\u0101pes ac\u012bs (bie\u017ei tikai vien\u0101 ac\u012b, da\u017ereiz ab\u0101s ac\u012bs vienlaic\u012bgi - MOGAD gad\u012bjum\u0101 tas ir bie\u017e\u0101k nek\u0101 citu l\u012bdz\u012bgu slim\u012bbu gad\u012bjum\u0101).<\/li>\n\n\n\n<li><strong>Muguras smadzenes<\/strong> - Paral\u012bzes, nejut\u012bguma, urin\u0113\u0161anas probl\u0113mu simptomi<\/li>\n\n\n\n<li><strong>Smadzenes :<\/strong> Apjukums, epilepsijas l\u0113kmes, koordin\u0101cijas trauc\u0113jumi<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Wie_verlauft_die_Erkrankung\"><\/span>K\u0101 slim\u012bba progres\u0113?<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>MOGAD parasti notiek <strong>Stumj<\/strong>. Ir f\u0101zes, kur\u0101s iekaisums ir akt\u012bvs un simptomi par\u0101d\u0101s ar p\u0101rtraukumiem, un starp t\u0101m ir klus\u0101kas f\u0101zes.<br>P\u0113c epizodes daudzi pacienti p\u0101rsteidzo\u0161i labi atvese\u013cojas, lab\u0101k nek\u0101, piem\u0113ram, MS gad\u012bjum\u0101. Tas ir t\u0101p\u0113c, ka pa\u0161as nervu \u0161\u0137iedras bie\u017ei vien ir maz\u0101k boj\u0101tas nek\u0101 izol\u0101cijas sl\u0101nis, kas var da\u013c\u0113ji atjaunoties.<\/p>\n\n\n\n<p>Aptuveni pusei no slimniekiem dz\u012bves laik\u0101 ir tikai viens slim\u012bbas uzliesmojums. Otrai pusei ir atk\u0101rtotas l\u0113kmes, kas var izrais\u012bt palieko\u0161us trauc\u0113jumus, ja netiek \u0101rst\u0113tas.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Wie_haufig_ist_MOGAD\"><\/span>Cik izplat\u012bts ir MOGAD?<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>MOGAD ir reti sastopams, tikai aptuveni <strong>1-2 no 100 000 cilv\u0113kiem<\/strong> saslimst. At\u0161\u0137ir\u012bb\u0101 no daudz\u0101m cit\u0101m nervu sist\u0113mas autoim\u016bn\u0101m slim\u012bb\u0101m t\u0101 skar sievietes un v\u012brie\u0161us aptuveni vien\u0101d\u0101 skait\u0101. Ar \u0161o slim\u012bbu var saslimt ar\u012b b\u0113rni, kas bie\u017ei izpau\u017eas k\u0101 pla\u0161s smadze\u0146u iekaisums ar apjukumu un drudzi.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Was_lost_MOGAD_aus\"><\/span>Kas izraisa MOGAD?<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Pirmajai epizodei bie\u017ei seko <strong>Infekcija<\/strong> uz priek\u0161u. \u0136ermenis c\u012bn\u0101s pret patog\u0113nu un k\u013c\u016bdaini sajauc sava organisma strukt\u016bras ar ienaidnieku. Im\u016bnsist\u0113ma iem\u0101c\u0101s uzbrukt nepareizajam m\u0113r\u0137im, un t\u0101 sakot, nekad neapst\u0101jas. Prec\u012bzs c\u0113lonis v\u0113l nav piln\u012bb\u0101 noskaidrots. <\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Wie_wird_MOGAD_behandelt\"><\/span>K\u0101 tiek \u0101rst\u0113ts MOGAD?<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Pa\u0161laik nav \u012bpa\u0161i at\u013cautu z\u0101\u013cu MOGAD \u0101rst\u0113\u0161anai. Viens <strong>ak\u016bta l\u0113kme<\/strong> \u0101rst\u0113 ar liel\u0101m dev\u0101m <strong>Kortizona inf\u016bzijas<\/strong>, kas \u0101tri nom\u0101c iekaisumu. Ja ar to nepietiek <strong>Asins mazg\u0101\u0161ana<\/strong> (<em>Plazmafer\u0113ze<\/em>) kait\u012bg\u0101s antivielas var izvad\u012bt tie\u0161i no asin\u012bm.<\/p>\n\n\n\n<p>Uz <strong>Turpm\u0101ku recid\u012bvu profilakse<\/strong> Im\u016bnsist\u0113mas nomierin\u0101\u0161anai lieto da\u017e\u0101dus medikamentus, piem\u0113ram, vielas, kas samazina antivielas ra\u017eojo\u0161o \u0161\u016bnu darb\u012bbu. Pa\u0161laik kl\u012bniskajos izm\u0113\u0123in\u0101jumos tiek p\u0101rbaud\u012btas vair\u0101kas jaunas, m\u0113r\u0137tiec\u012bg\u0101kas z\u0101les, un tuv\u0101ko gadu laik\u0101 t\u0101s var\u0113tu tikt at\u013cautas.<\/p>\n\n\n\n<h1 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Wissenschaftliche_Einleitung_und_Definition\"><\/span>Zin\u0101tniskais ievads un defin\u012bcija<span class=\"ez-toc-section-end\"><\/span><\/h1>\n\n\n\n<p>Port\u0101ls <strong>Ar MOG antivielu saist\u012bta slim\u012bba (MOGAD)<\/strong> Ang\u013cu valod\u0101: <em>Miel\u012bna oligodendroc\u012btu glikoprote\u012bna antivielu saist\u012bt\u0101 slim\u012bba<\/em> ir reta centr\u0101l\u0101s nervu sist\u0113mas (CNS) iekaisuma autoim\u016bna slim\u012bba, kas kop\u0161 2018. gada ir atz\u012bta par patst\u0101v\u012bgu vien\u012bbu ar saviem diagnostikas krit\u0113rijiem. Iepriek\u0161 t\u0101 tika uzskat\u012bta par multipl\u0101s sklerozes (MS) paveidu vai neiromiel\u012bta optikas spektra trauc\u0113jumu (NMOSD).<\/p>\n\n\n\n<p>Slim\u012bbas pamatelements ir patolo\u0123iska autoantivielu (IgG) veido\u0161an\u0101s pret im\u016bnsist\u0113mu. <strong>Miel\u012bna oligodendroc\u012btu glikoprote\u012bns (MOG)<\/strong>, transmembr\u0101na prote\u012bns, kas atrodas CNS oligodendroc\u012btu miel\u012bna apvalka \u0101r\u0113j\u0101 sl\u0101n\u012b. \u0160\u012bs antivielas boj\u0101 miel\u012bna apvalkus un izraisa rakstur\u012bgo perivenul\u0101ro demieliniz\u0101ciju.<\/p>\n\n\n\n<p>Kl\u012bniski MOGAD galvenok\u0101rt izpau\u017eas k\u0101 redzes nerva neir\u012bts, transvers\u0101ls miel\u012bts un ak\u016bts disemin\u0113ts encefalomiel\u012bts (ADEM). Slim\u012bba parasti recidiv\u0113 un skar redzes nervu, muguras smadzenes un ret\u0101k galvas smadzenes. Vid\u0113jais slim\u012bbas s\u0101kuma vecums ir no 30 l\u012bdz 35 gadiem; at\u0161\u0137ir\u012bb\u0101 no NMOSD gandr\u012bz vienl\u012bdz bie\u017ei slimo sievietes un v\u012brie\u0161i.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Abgrenzung_von_MOGAD_NMOSD_und_MS\"><\/span>MOGAD, NMOSD un MS diferenci\u0101cija<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><td><strong>Funkcija<\/strong><\/td><td><strong>MOGAD<\/strong><\/td><td><strong>AQP4+ NMOSD<\/strong><\/td><td><strong>Multipl\u0101 skleroze<\/strong><\/td><\/tr><\/thead><tbody><tr><td>M\u0113r\u0137a antig\u0113ns<\/td><td>MOG (oligodendroc\u012bti)<\/td><td>Akvapor\u012bns-4 (astroc\u012bti)<\/td><td>Nav specifisku autoantivielu<\/td><\/tr><tr><td>Antivielu izotips<\/td><td>IgG1 (iepriek\u0161)<\/td><td>IgG1 (iepriek\u0161)<\/td><td>Oligoklon\u0101lais IgG (CSF)<\/td><\/tr><tr><td>Prim\u0101rie \u0161\u016bnu boj\u0101jumi<\/td><td>Oligodendroc\u012bti\/ miel\u012bns<\/td><td>Astroc\u012bti (prim\u0101rie)<\/td><td>Oligodendroc\u012bti<\/td><\/tr><tr><td>Histolo\u0123ija<\/td><td>Perivenul\u0101r\u0101 demieliniz\u0101cija, CD4+<\/td><td>Astroc\u012btu boj\u0101jumi, granuloc\u012bti<\/td><td>Periaksi\u0101l\u0101s pl\u0101ksn\u012btes<\/td><\/tr><tr><td>Dzimums (F:M)<\/td><td>~1:1<\/td><td>~9:1<\/td><td>~3:1<\/td><\/tr><tr><td>Komplementa aktiviz\u0113\u0161ana<\/td><td>M\u0113reni (maz\u0101k MAC)<\/td><td>Strong (MAC form\u0113\u0161ana)<\/td><td>Zema<\/td><\/tr><tr><td>OKB cerebrospin\u0101laj\u0101 \u0161\u0137idrum\u0101<\/td><td>Reti (&lt;10%)<\/td><td>Reiz\u0113m<\/td><td>Bie\u017ei (&gt;90%)<\/td><\/tr><tr><td>Kurss<\/td><td>Atjauno\u0161an\u0101s; bie\u017ei vien labi atvese\u013cojas<\/td><td>Ar vilces formu; uzkr\u0101j invalidit\u0101ti<\/td><td>Bie\u017ei progedient<\/td><\/tr><tr><td>At\u013caut\u0101s terapijas<\/td><td>Nav (no 2026. gada)<\/td><td>Ekulizumabs, ublituksimabs, satralizumabs<\/td><td>Daudzi DMT<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h1 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"MOG-Protein_%E2%80%93_Struktur_und_physiologische_Funktion\"><\/span>MOG prote\u012bns - strukt\u016bra un fiziolo\u0123isk\u0101 funkcija<span class=\"ez-toc-section-end\"><\/span><\/h1>\n\n\n\n<p>MOG (miel\u012bna oligodendroc\u012bta glikoprote\u012bns) ir <strong>I tipa transmembr\u0101na prote\u012bns<\/strong> ar kop\u0113jo garumu 218 aminosk\u0101bes, kas ir izteikts tikai CNS. Tas ir im\u016bnglobul\u012bnu super\u0123imenes loceklis, un ar aptuveni 0,01-0,05 % \u012bpatsvaru no kop\u0113j\u0101 miel\u012bna prote\u012bna veido kvantitat\u012bvi nelielu, bet imunolo\u0123iski \u013coti noz\u012bm\u012bgu miel\u012bna apvalka sast\u0101vda\u013cu.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Strukturdomanen\"><\/span>Strukt\u016bras dom\u0113ni<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Ekstracelul\u0101rais Ig-V l\u012bdz\u012bgais dom\u0113ns (AS 1-120): satur kritisko CC\u2018 cilpas apgabalu (Pro42, His103, Ser104), kas ir vissvar\u012bg\u0101k\u0101 epitopa saist\u012b\u0161anas vieta MOG-IgG.<\/li>\n\n\n\n<li>Vienp\u0101rejas transmembr\u0101nas spir\u0101le: noenkuro prote\u012bnu miel\u012bna membr\u0101n\u0101.<\/li>\n\n\n\n<li>\u012ass citoplazmas C-termin\u0101lais dom\u0113ns: iesp\u0113jams, mijiedarbojas ar citoskeletu.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Physiologische_Funktionen\"><\/span>Fiziolo\u0123isk\u0101s funkcijas<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Adh\u0113zijas molekula: Miel\u012bna apvalka struktur\u0101l\u0101 integrit\u0101te, iesp\u0113jams, sabl\u012bv\u0113jot miel\u012bna pl\u0101ksn\u012btes.<\/li>\n\n\n\n<li>Mijiedarb\u012bba ar komplementa sist\u0113mas C1q (fiziolo\u0123iska)<\/li>\n\n\n\n<li>Mijiedarb\u012bba ar nervu aug\u0161anas faktoru (NGF)<\/li>\n\n\n\n<li>Masali\u0146u v\u012brusa receptoru (kl\u012bniski svar\u012bgi p\u0113cinfekcijas ADEM gad\u012bjum\u0101).<\/li>\n\n\n\n<li>Mikrotubulu stabiliz\u0101cija oligodendroc\u012btos<\/li>\n\n\n\n<li>Ekspresija: v\u0113l\u012bn\u0101 oligodendroc\u012btu diferenci\u0101cijas stadij\u0101; tikai p\u0113c s\u0101kotn\u0113j\u0101s mieliniz\u0101cijas.<\/li>\n<\/ul>\n\n\n\n<p>MOG-IgG autoantivielas galvenok\u0101rt atpaz\u012bst <strong>Konform\u0101cijas epitopi<\/strong> ekstracelul\u0101r\u0101 dom\u0113na. T\u0101 k\u0101 MOG atrodas miel\u012bna apvalka \u0101r\u0113j\u0101 virsm\u0101, tas ir tie\u0161i pieejams cirkul\u0113jo\u0161\u0101m antiviel\u0101m un im\u016bnkompleksiem, kas ir iz\u0161\u0137iro\u0161a at\u0161\u0137ir\u012bba no intracelul\u0101riem antig\u0113niem.<\/p>\n\n\n\n<h1 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Pathogenese_und_Immunpathologie\"><\/span>Pato\u0123en\u0113ze un im\u016bnpatolo\u0123ija<span class=\"ez-toc-section-end\"><\/span><\/h1>\n\n\n\n<p>MOGAD pato\u0123en\u0113ze ir daudzpak\u0101pju process, kas ietver perif\u0113ro im\u016bnsist\u0113mas aktiv\u0101ciju, migr\u0101ciju p\u0101ri hematoencefaliskajai barjerai (BBB) un CNS lok\u0101los efektoru meh\u0101nismus. Ne T \u0161\u016bnas, ne B \u0161\u016bnas vienas pa\u0161as par sevi nav pietiekami patog\u0113nas, slim\u012bbu izraisa abu adapt\u012bv\u0101s im\u016bnsist\u0113mas atzaru siner\u0123iska mijiedarb\u012bba.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Trigger_und_initiale_Aktivierung\"><\/span>Palaidnis un s\u0101kotn\u0113j\u0101 aktiviz\u0113\u0161ana<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Galvenie s\u0101kotn\u0113jie ierosin\u0101t\u0101ji ir \u0161\u0101di. <strong>Infekcijas<\/strong> apspriests: Infekcijas prodroms ir dokument\u0113ts 37-70 % MOGAD pacientiem (bie\u017e\u0101k nek\u0101 NMOSD ar 15-35 %). Meh\u0101nismi ir \u0161\u0101di:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Molekul\u0101r\u0101 mimikrija - patog\u0113nu epitopi ir struktur\u0101li l\u012bdz\u012bgi MOG CC\u2018 cilpas apgabalam, piem\u0113ram, SARS-CoV-2 sekvences vai masali\u0146u v\u012brusi.<\/li>\n\n\n\n<li>Bystander aktiv\u0101cija - nespecifiska iekaisuma reakcija aktiviz\u0113 neakt\u012bvos autoreakt\u012bvos limfoc\u012btus.<\/li>\n\n\n\n<li>Mikrobu superantig\u0113nu izrais\u012bta poliklon\u0101lo B \u0161\u016bnu aktiv\u0101cija<\/li>\n<\/ul>\n\n\n\n<p>\u0122en\u0113tiskai nosliecei ir noz\u012bme, bet konkr\u0113ti riska haplotipi nav noteikti. At\u0161\u0137ir\u012bb\u0101 no MS nav aprakst\u012btas konsekventas HLA saist\u012bbas.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"T-Zell-vermittelte_Pathogenese\"><\/span>T-\u0161\u016bnu medi\u0113t\u0101 pato\u0123en\u0113ze<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>MOG specifiskaj\u0101m CD4+ T \u0161\u016bn\u0101m ir b\u016btiska noz\u012bme MOGAD pato\u0123en\u0113z\u0113. Dz\u012bvnieku mode\u013cos (EAE) antivielas vienas pa\u0161as par sevi nav patog\u0113nas; t\u0101m nepiecie\u0161amas encefalitog\u0113n\u0101s T \u0161\u016bnas k\u0101 l\u012bdzfaktori. CD4+ ce\u013c\u0161 sast\u0101v no vair\u0101kiem posmiem:<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Phase_1_%E2%80%93_Periphere_Aktivierung\"><\/span>1. f\u0101ze - Perif\u0113risk\u0101 aktiviz\u0101cija<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>MOG pept\u012bdus ra\u017eo antig\u0113nu prezent\u0113jo\u0161\u0101s \u0161\u016bnas (APC), izmantojot <strong>MHC-II molekulas<\/strong> uz naiv\u0101m CD4+ T \u0161\u016bn\u0101m. Iev\u0113r\u012bbas cien\u012bgi: <em>MOG pept\u012bdi var tie\u0161i saist\u012bties ar perif\u0113raj\u0101m MHC II molekul\u0101m.<\/em>, bez turpm\u0101kas apstr\u0101des. Tas var\u0113tu izskaidrot perif\u0113risk\u0101s nervu sist\u0113mas iesaist\u012b\u0161anos.<\/p>\n\n\n\n<p>Efektor\u0161\u016bnu apak\u0161grupas, kas var izrais\u012bt EAE neatkar\u012bgi viena no otras, ir \u0161\u0101das. <strong>Th1, Th17 un Th9<\/strong>. Th17 \u0161\u016bnas ir \u012bpa\u0161i svar\u012bgas MOGAD, jo Th17 citok\u012bni (IL-17, IL-21) ir iev\u0113rojami paaugstin\u0101ti grie\u0161anas epizo\u017eu laik\u0101.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Phase_2_%E2%80%93_BHS-Penetration\"><\/span>2. posms - BHS iespie\u0161an\u0101s<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Aktiv\u0113t\u0101s CD4+ T \u0161\u016bnas ekspres\u0113 specifiskas adh\u0113zijas molekulas (integr\u012bnus, selekt\u012bnus) un hemok\u012bnu receptorus (jo sevi\u0161\u0137i T-\u0161\u016bnas). <strong>CCR6<\/strong>), kas \u013cauj tiem iek\u013c\u016bt CNS. CCR6+ Th17 \u0161\u016bnas saist\u0101s ar CCL20, kas konstitut\u012bvi ekspres\u0113jas dz\u012bslen\u0113 un caur to iek\u013c\u016bst subarahnoid\u0101laj\u0101 telp\u0101.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Matriksa metaloprotein\u0101zes (MMP-2, MMP-9)<br>BBB baz\u0101l\u0101s membr\u0101nas degrad\u0101cija<\/li>\n\n\n\n<li>Neitrofilu NET (neitrofilu ekstracelul\u0101r\u0101s lamatas)<br>Sniedz T \u0161\u016bn\u0101m inici\u0101cijas f\u0101z\u0113 kostimul\u0113jo\u0161us sign\u0101lus.<\/li>\n\n\n\n<li>Tromboc\u012bti<br>CD4+ T \u0161\u016bnu prolifer\u0101ciju un diferenci\u0101ciju uz Th1\/Th17, izmantojot citok\u012bnus un adh\u0113zijas molekulas.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Phase_3_%E2%80%93_Perivaskulare_Reaktivierung\"><\/span>3. f\u0101ze - Perivaskul\u0101ra reaktiv\u0101cija<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Perivaskul\u0101raj\u0101 un subarahnoid\u0101laj\u0101 telp\u0101 MOG specifisk\u0101s T \u0161\u016bnas reaktiv\u0113 viet\u0113jie ar MOG apg\u0101d\u0101tie APC (mikroglijas, dendr\u012bt\u0161\u016bnas). \u0160\u012b reaktiv\u0101cija izraisa faktisko iekaisuma kask\u0101di: T\u0101 izraisa proiekaisuma cito\u0137\u012bnu sekr\u0113ciju, turpm\u0101ku leikoc\u012btu verv\u0113\u0161anu un oligodendroc\u012btu boj\u0101jumus.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"B-Zell-_und_Antikorper-vermittelte_Pathogenese\"><\/span>B-\u0161\u016bnu un antivielu medi\u0113t\u0101 pato\u0123en\u0113ze<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>MOG specifisk\u0101s B \u0161\u016bnas un plazmas \u0161\u016bnas ir galvenie patog\u0113no IgG1 autoantivielu ra\u017eot\u0101ji. Tom\u0113r B \u0161\u016bnu loma ir pla\u0161\u0101ka par antivielu ra\u017eo\u0161anu:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Antig\u0113na prezent\u0101cija - B \u0161\u016bnas var saist\u012bt MOG konform\u0101cijas epitopus (CC\u2018 cilpas pro42, his103, ser104), izmantojot BCR, un darboties k\u0101 T \u0161\u016bnu APC.<\/li>\n\n\n\n<li>Th17 diferenci\u0101cijas veicin\u0101\u0161ana - B \u0161\u016bnas izdala IL-6, kas kop\u0101 ar TGF-\u03b2 veicina Th17 diferenci\u0101ciju.<\/li>\n\n\n\n<li>MAPK un AKT signaliz\u0101cijas aktiviz\u0113\u0161ana - BCR saist\u012b\u0161an\u0101s ar MOG aktiviz\u0113 \u0161os signaliz\u0101cijas ce\u013cus intracelul\u0101ri.<\/li>\n\n\n\n<li>Intracelul\u0101r\u0101 kalcija palielin\u0101\u0161an\u0101s - izraisa ar stresu saist\u012bto signaliz\u0101cijas kask\u0101\u017eu aktiviz\u0113\u0161anos.<\/li>\n<\/ul>\n\n\n\n<p>Liel\u0101k\u0101 da\u013ca MOG-IgG antivielu veidojas perif\u0113rij\u0101 (oligoklon\u0101las joslas KCM tikai ~10 % gad\u012bjumu, sal\u012bdzin\u0101jumam: MS ~90 %). Antivielas ir <strong>divv\u0113rt\u012bgo saistvielu<\/strong> ar MOG, abi Fab posmi vienlaic\u012bgi saist\u0101s ar div\u0101m blakus eso\u0161\u0101m MOG molekul\u0101m. Tas izraisa maz\u0101k efekt\u012bvu C1q piesaist\u012b\u0161anu, sal\u012bdzinot ar monovalento AQP4-IgG saist\u012b\u0161anos NMOSD.<\/p>\n\n\n\n<h1 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Molekulare_Signalwege_und_Effektormechanismen\"><\/span>Molekul\u0101r\u0101s signaliz\u0101cijas ce\u013ci un iedarb\u012bbas meh\u0101nismi<span class=\"ez-toc-section-end\"><\/span><\/h1>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Signalweg_1_%E2%80%93_Klassischer_Komplementweg_CDC\"><\/span>Signaliz\u0101cijas ce\u013c\u0161 1 - klasiskais komplementa ce\u013c\u0161 (CDC)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Kad MOG-IgG1 (un MOG-IgG3) saist\u0101s ar oligodendroc\u012btu MOG, MOG-IgG1 un MOG-IgG3 <strong>klasiskais papildino\u0161ais mar\u0161ruts<\/strong> ir aktiviz\u0113ti. Tom\u0113r komplementa aktiv\u0101cija MOGAD ir v\u0101j\u0101ka nek\u0101 AQP4+ NMOSD:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>C1q saist\u012b\u0161an\u0101s ar saist\u012bto IgG1 antivielu Fc da\u013cu \u2192 C1r un C1s aktiv\u0101cija<\/li>\n\n\n\n<li>C4 sa\u0161\u0137el\u0161ana \u2192 C4a + C4b; C4b + C2 \u2192 C3 konvert\u0101ze (C4b2a)<\/li>\n\n\n\n<li>C3 sa\u0161\u0137el\u0161ana \u2192 C3a (anafilatoks\u012bns) + C3b (opson\u012bns)<\/li>\n\n\n\n<li>C3b \u2192 C5 konvert\u0101ze \u2192 C5 sa\u0161\u0137el\u0161ana \u2192 C5a (sp\u0113c\u012bgs anafilatoks\u012bns) + C5b<\/li>\n\n\n\n<li>C5b + C6, C7, C8, C9 \u2192 membr\u0101nas uzbrukuma komplekss (MAC, C5b-9): Tie\u0161a oligodendroc\u012btu l\u012bze<\/li>\n<\/ul>\n\n\n\n<p>Svar\u012bgi: MOGAD pacientu smadze\u0146u smadze\u0146u smadze\u0146u \u0161\u0137idrum\u0101 C3a un C5a ir iev\u0113rojami palielin\u0101ti (sal\u012bdzin\u0101mi ar AQP4+ NMOSD), bet MAC komplekss (C5b-9) nav iev\u0113rojami palielin\u0101ts. <strong>iev\u0113rojami zem\u0101ka<\/strong> nek\u0101 NMOSD. Tas ir saist\u012bts ar divv\u0113rt\u012bgo IgG saist\u012b\u0161anos, kas ir maz\u0101k efekt\u012bva C1q grup\u0113\u0161anai, un sal\u012bdzino\u0161i zemo komplementa regulatoru bl\u012bvumu uz oligodendroc\u012btiem (maz\u0101k CR1, MCP, HRF nek\u0101 uz citiem \u0161\u016bnu tipiem).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Signalweg_2_%E2%80%93_Fc%CE%B3-Rezeptor-Weg_FcR-vermittelt\"><\/span>2. signaliz\u0101cijas ce\u013c\u0161 - Fc\u03b3 receptoru ce\u013c\u0161 (ar FcR starpniec\u012bbu)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>LMU p\u0113t\u012bjumi (Mader, Kawakami, Meinl, 2024 PNAS) par\u0101d\u012bja, ka Fc\u03b3 receptoru (Fc\u03b3R) medi\u0113tie meh\u0101nismi. <strong>l\u012bdz aptuveni 50 % miel\u012bna boj\u0101jumu.<\/strong> un t\u0101p\u0113c ir l\u012bdzv\u0113rt\u012bgi komplementa aktiviz\u0101cijai:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Fc\u03b3RIII<\/strong> (<strong>CD16<\/strong>) uz NK \u0161\u016bn\u0101m un makrof\u0101giem<br>Saist\u0101s ar MOG saist\u012bt\u0101 IgG1 Fc da\u013c\u0101 \u2192 ADCC (no antiviel\u0101m atkar\u012bga \u0161\u016bnu citotoksicit\u0101te)<\/li>\n\n\n\n<li><strong>Fc\u03b3RI\/II\/III<\/strong> uz makrof\u0101giem un monoc\u012btiem<br>MOG-opsoniz\u0113tu oligodendroc\u012btu fragmentu fagocitoze (ADCP)<\/li>\n\n\n\n<li>Iz\u0161\u0137iro\u0161ais: otrais FcR patomeh\u0101nisms<br>T-\u0161\u016bnu aktiviz\u0101cijas pastiprin\u0101\u0161ana, kas notiek tikai caur Fc receptoriem, NE komplementa ce\u013cu.<\/li>\n\n\n\n<li><strong>Fc\u03b3R<\/strong> par dendr\u012btiskaj\u0101m \u0161\u016bn\u0101m<br>MOG-IgG pies\u0101tin\u0101tu oligodendroc\u012btu antig\u0113nu apstr\u0101des un pasnieg\u0161anas atvieglo\u0161ana MOG specifiskaj\u0101m T \u0161\u016bn\u0101m.<\/li>\n<\/ul>\n\n\n\n<p>Kl\u012bnisk\u0101 noz\u012bme: T\u0101 k\u0101 past\u0101v divi neatkar\u012bgi patog\u0113n\u0101s att\u012bst\u012bbas ce\u013ci, terapeitiskaj\u0101m pieej\u0101m j\u0101b\u016bt \u0161\u0101d\u0101m <strong>Abi meh\u0101nismi<\/strong> lai sasniegtu maksim\u0101lu efektivit\u0101ti.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Signalweg_3_%E2%80%93_IL-6JAK-STAT3-Weg\"><\/span>Signaliz\u0101cijas ce\u013c\u0161 3 - IL-6\/JAK-STAT3 ce\u013c\u0161<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>IL-6 ir MOGAD im\u016bnpatog\u0113zes centr\u0101lais mediators un darbojas vair\u0101kos l\u012bme\u0146os:<\/p>\n\n\n\n<p>IL-6 saist\u0101s ar savu receptoru (IL-6R\u03b1\/gp130 komplekss), kas izraisa <strong>JAK1\/2 fosforil\u0113\u0161ana<\/strong> vadi. Tas galvenok\u0101rt aktiviz\u0113 <strong>STAT3<\/strong>, kas kalpo k\u0101 transkripcijas faktors:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Th17 diferenci\u0101cija<\/strong><br>IL-6 + TGF-\u03b2 \u2192 ROR\u03b3t ekspresija \u2192 IL-17A\/F ra\u017eo\u0161ana; IL-6 + IL-23 \u2192 Th17 fenotipa uztur\u0113\u0161ana.<\/li>\n\n\n\n<li><strong>Folikul\u0101r\u0101s T pal\u012bg\u0161\u016bnas<\/strong> (<strong>Tfh<\/strong>)<br>IL-6 \u2192 STAT3 \u2192 Bcl6 ekspresija \u2192 Germin\u0101l\u0101 centra B \u0161\u016bnu nobrie\u0161ana un IgG klases mai\u0146a<\/li>\n\n\n\n<li><strong>B \u0161\u016bnu nobrie\u0161ana l\u012bdz plazmas \u0161\u016bn\u0101m<\/strong><br>IL-6 veicina diferenci\u0101ciju, izmantojot STAT3\/Blimp-1 asi<\/li>\n\n\n\n<li><strong>Treg funkcijas nom\u0101k\u0161ana<\/strong><br>IL-6 nom\u0101c FoxP3 ekspresiju, kas novirza Treg\/Th17 l\u012bdzsvaru uz iekaisuma pusi.<\/li>\n<\/ul>\n\n\n\n<p>Terapeitisk\u0101 noz\u012bme: IL-6 blok\u0101de (piem\u0113ram, tocilizumabs, satralizumabs) p\u0101rtrauc \u0161o ciklu. <strong><em>Satralizumabs<\/em><\/strong> (anti-IL-6R) pa\u0161laik tiek p\u0113t\u012bts MOGAD 3. f\u0101zes p\u0113t\u012bjum\u0101 METEOROID.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Signalweg_4_%E2%80%93_MAPK-_und_AKT-Signalwege_B-Zellen\"><\/span>Signaliz\u0101cijas ce\u013c\u0161 4 - MAPK un AKT signaliz\u0101cijas ce\u013ci (B \u0161\u016bnas)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>BCR saist\u012b\u0161an\u0101s ar MOG konform\u0101cijas epitopiem, kas aktiviz\u0113ti B \u0161\u016bn\u0101s:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>MAPK ce\u013c\u0161<\/strong> (<strong>MEK\/ERK<\/strong>)<br>B \u0161\u016bnu prolifer\u0101cijas un diferenci\u0101cijas veicin\u0101\u0161ana<\/li>\n\n\n\n<li><strong>PI3K\/AKT ce\u013c\u0161<\/strong><br>B \u0161\u016bnu izdz\u012bvo\u0161ana un diferenci\u0101cija par plazmas \u0161\u016bn\u0101m<\/li>\n\n\n\n<li><strong>Kalcija piepl\u016bdums<\/strong><br>Kalcineur\u012bna\/NFAT ass aktiviz\u0101cija \u2192 Citok\u012bnu veido\u0161an\u0101s<\/li>\n\n\n\n<li><strong>NK \u0161\u016bnu aktiviz\u0113\u0161ana<\/strong><br>BCR-MOG saist\u012b\u0161an\u0101s izraisa NK \u0161\u016bnu medi\u0113tu citotoksicit\u0101ti<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Signalweg_5_%E2%80%93_Th17-Zytokin-Netzwerk_im_ZNS\"><\/span>5. signaliz\u0101cijas ce\u013c\u0161 - Th17 citok\u012bnu t\u012bkls CNS<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>CNS Th17 \u0161\u016bnas uztur iekaisuma vidi, izmantojot vair\u0101kus mediatorus:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>IL-17A un IL-17F<\/strong><br>Aktiviz\u0113 astroc\u012btus un mikrogliju; izraisa \u0137\u012bmok\u012bnu (CXCL-1\/5\/8) izdal\u012b\u0161anos, kas rekrut\u0113 neitrof\u012b\u013cus.<\/li>\n\n\n\n<li><strong>IL-21<\/strong> (auto- un parakr\u012bn\u0101s)<br>Pastiprina Th17 diferenci\u0101ciju; veicina B \u0161\u016bnu diferenci\u0101ciju un IgG klases mai\u0146u (\u012bpa\u0161i IgG1).<\/li>\n\n\n\n<li><strong>IL-22<\/strong><br>BBB integrit\u0101tes disregul\u0101cija<\/li>\n\n\n\n<li><strong>GM-CSF<\/strong> (<strong>caur IL-23<\/strong>)<br>Aktiviz\u0113 mikrogliju un makrof\u0101gus, palielina viet\u0113jo demieliniz\u0101ciju.<\/li>\n\n\n\n<li><strong>CXCL13<\/strong><br>B \u0161\u016bnu \u0137\u012bmotaksis perivaskul\u0101raj\u0101s telp\u0101s \u2192 lok\u0101la antivielu veido\u0161an\u0101s<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Signalwege_%E2%80%93_Ubersicht\"><\/span>Signaliz\u0101cijas ce\u013ci - p\u0101rskats<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><td><strong>Sign\u0101la ce\u013c\u0161<\/strong><\/td><td><strong>Galven\u0101s molekulas<\/strong><\/td><td><strong>Efekts<\/strong><\/td><td><strong>Terapeitiskie m\u0113r\u0137i<\/strong><\/td><\/tr><\/thead><tbody><tr><td>Klasiskais papildu mar\u0161ruts<\/td><td>C1q, C3, C5, MAC (C5b-9)<\/td><td>Tie\u0161\u0101 oligodendroc\u012btu l\u012bze<\/td><td>C5 inhibitori (ekulizumabs), C3 inhibitori<\/td><\/tr><tr><td>Fc\u03b3R ce\u013c\u0161 (ADCC\/ADCP)<\/td><td>Fc\u03b3RI\/II\/III, NK \u0161\u016bnas, makrof\u0101gi<\/td><td>Citotoksicit\u0101te, fagocitoze, T-\u0161\u016bnu potenc\u0113\u0161ana<\/td><td>FcRn inhibitori (IgG degrad\u0101cija), FcR blok\u0101de<\/td><\/tr><tr><td>IL-6\/JAK-STAT3<\/td><td>IL-6, IL-6R\u03b1, gp130, JAK1\/2, STAT3, ROR\u03b3t<\/td><td>Th17 diferenci\u0101cija, B \u0161\u016bnu nobrie\u0161ana, IgG ra\u017eo\u0161ana<\/td><td>Anti-IL-6R (tocilizumabs, satralizumabs)<\/td><\/tr><tr><td>PI3K\/AKT\/MAPK (B \u0161\u016bnas)<\/td><td>BTK, PI3K, AKT, ERK, NFAT<\/td><td>B \u0161\u016bnu aktiviz\u0101cija, plazmatisko \u0161\u016bnu nobrie\u0161ana.<\/td><td>BTK inhibitori (ibrutinibs, tolebrutinibs)<\/td><\/tr><tr><td>Th17 citok\u012bnu t\u012bkls<\/td><td>IL-17, IL-21, IL-22, GM-CSF, CXCL13<\/td><td>BBB boj\u0101jums, leikoc\u012btu rekrut\u0113\u0161ana, demieliniz\u0101cija<\/td><td>Anti-IL-17, Anti-IL-21<\/td><\/tr><tr><td>FcRn-IgG p\u0101rstr\u0101de<\/td><td>FcRn (jaundzimu\u0161o Fc receptoru)<\/td><td>Pagarin\u0101ts IgG pusperiods<\/td><td>Anti-FcRn (rozanoliksizumabs)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h1 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Relevante_Rezeptoren_und_Zielmolekule\"><\/span>Attiec\u012bgie receptori un m\u0113r\u0137a molekulas<span class=\"ez-toc-section-end\"><\/span><\/h1>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"MOG_selbst_als_Zielstruktur_kein_klassischer_Rezeptor\"><\/span>MOG k\u0101 m\u0113r\u0137a strukt\u016bra (nevis klasisks receptoru).<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>MOGAD gad\u012bjum\u0101 MOG prote\u012bns darbojas k\u0101 antig\u0113ns, nevis k\u0101 sign\u0101lreceptors. Tom\u0113r patofiziolo\u0123iski noz\u012bm\u012bgas ir \u0161\u0101das mijiedarb\u012bbas:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>C1q saist\u012b\u0161ana<\/strong><br>MOG var fiziolo\u0123iski saist\u012bt C1q, kas patolo\u0123isku antivielu p\u0101rkl\u0101juma gad\u012bjum\u0101 izraisa komplementa aktiv\u0101ciju.<\/li>\n\n\n\n<li><strong>DC Z\u012aME (CD209)<\/strong><br>Lekt\u012bnu receptoru uz dendr\u012bt\u0161\u016bn\u0101m; var saist\u012bt MOG un veicin\u0101t antig\u0113na prezent\u0101ciju.<\/li>\n\n\n\n<li><strong>Masali\u0146u v\u012brusa receptoru<\/strong>_<br>MOG kalpo k\u0101 ien\u0101ko\u0161\u0101 molekula masali\u0146u v\u012brusiem, kas var\u0113tu izskaidrot p\u0113cinfekciozo ADEM b\u0113rniem.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Fc%CE%B3-Rezeptoren_Fc%CE%B3R\"><\/span>Fc\u03b3 receptori (Fc\u03b3R)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Im\u016bn\u0161\u016bnu Fc\u03b3 receptori ir galvenie IgG1 medi\u0113to boj\u0101jumu izrais\u012bt\u0101ji:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Fc\u03b3RI (CD64)<\/strong><br>Augsta afinit\u0101te, uz makrof\u0101giem un dendr\u012bt\u0161\u016bn\u0101m; ADCP un antig\u0113na prezent\u0101cijas starpniec\u012bba.<\/li>\n\n\n\n<li><strong>Fc\u03b3RIII (CD16)<\/strong><br>Zema afinit\u0101te pret NK \u0161\u016bn\u0101m; galvenais ADCC mediators pret MOG-opsoniz\u0113tiem oligodendroc\u012btiem.<\/li>\n\n\n\n<li><strong>Fc\u03b3RIIA\/B (CD32A\/B)<\/strong><br>Aktiviz\u0113\u0161ana vai inhib\u0113\u0161ana; B \u0161\u016bnu aktiv\u0101cijas un fagocitozes modul\u0101cija.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Neonataler_Fc-Rezeptor_FcRn\"><\/span>Jaundzimu\u0161o Fc receptori (FcRn)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>FcRn (\u03b22m\/FcRn-\u03b1 komplekss) ir atbild\u012bgs par IgG antivielu intracelul\u0101ro p\u0101rstr\u0101di. Tas saista IgG pask\u0101bin\u0101t\u0101s endosom\u0101s (pH 6,0) un nov\u0113r\u0161 t\u0101 lizosom\u0101lo degrad\u0101ciju, t\u0101d\u0113j\u0101di pagarinot IgG pusperiodu l\u012bdz aptuveni 21 dienai.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>MOGAD gad\u012bjum\u0101 FcRn izraisa past\u0101v\u012bgu patog\u0113n\u0101 MOG-IgG1 cirkul\u0101ciju.<\/li>\n\n\n\n<li>Terapeitisk\u0101 blo\u0137\u0113\u0161ana, ko izraisa <em>Rozanoliksizumabs<\/em> (anti-FcRn IgG4): Piespie\u017e lizosom\u0101lo IgG no\u0101rd\u012b\u0161anos un samazina plazmas IgG par ~ 50%.<\/li>\n\n\n\n<li>FcRn ekspresija - epit\u0113lija \u0161\u016bnas, endot\u0113lija \u0161\u016bnas, monoc\u012bti, hepatoc\u012bti.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"IL-6-Rezeptor_IL-6R%CE%B1_gp130\"><\/span>IL-6 receptoru (IL-6R\u03b1 \/ gp130)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>IL-6 receptoru veido ligandu saisto\u0161\u0101 \u03b1 apak\u0161vien\u012bba (IL-6R\u03b1, CD126) un signaliz\u0101cijas ko-receptors gp130 (IL-6R\u03b2, CD130). Divi signaliz\u0101cijas re\u017e\u012bmi:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Klasisk\u0101 signaliz\u0101cija<\/strong><br>Membr\u0101n\u0101 saist\u012bts IL-6R\u03b1 uz T-\u0161\u016bn\u0101m, B-\u0161\u016bn\u0101m, monoc\u012btiem \u2192 IL-6\/IL-6R\u03b1\/gp130 komplekss \u2192 JAK1\/2 \u2192 STAT3, STAT1, MAPK, PI3K\/AKT<\/li>\n\n\n\n<li><strong>Transsignaliz\u0113\u0161ana<\/strong><br>\u0160\u0137\u012bsto\u0161ais IL-6R\u03b1 (sIL-6R) saista IL-6 un aktiviz\u0113 gp130 pat \u0161\u016bn\u0101s, kur\u0101s nav membr\u0101n\u0101 saist\u012bt\u0101 IL-6R\u03b1 (piem\u0113ram, BBB endot\u0113lija \u0161\u016bn\u0101s).<\/li>\n<\/ul>\n\n\n\n<p>Attiec\u012bg\u0101 pak\u0101rtot\u0101 ietekme: ROR\u03b3t ekspresija (Th17), Bcl-6 (Tfh un germin\u0101lie centri), Blimp-1 (plazmatisk\u0101s \u0161\u016bnas), FoxP3 nom\u0101k\u0161ana (Treg).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"T-Zell-Rezeptor_TCR_und_Kostimulationsmolekule\"><\/span>T-\u0161\u016bnu receptoru (TCR) un kostimul\u0101cijas molekulas.<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>TCR\/MHC-II-MOG pept\u012bda komplekss<\/strong><br>MOG specifisko CD4+ T \u0161\u016bnu centr\u0101l\u0101 aktiviz\u0101cijas ass<\/li>\n\n\n\n<li><strong>CD28\/B7<\/strong><br>Kostimul\u0101cija T-\u0161\u016bnu aktiviz\u0101cijas laik\u0101<\/li>\n\n\n\n<li><strong>CCR6\/CCL20 ass<\/strong><br>CCR6 uz Th17 \u0161\u016bn\u0101m saist\u0101s ar CCL20 pie dz\u012bslu pl\u0113ves \u2192 iek\u013c\u016b\u0161ana CNS<\/li>\n\n\n\n<li><strong>CXCR3\/CXCL10<\/strong><br>Th1 \u0161\u016bnu \u0137\u012bmotaksis iekaisuma zon\u0101s<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Komplementrezeptoren\"><\/span>Komplementa receptori<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>C1qR<\/strong><br>Veic C1q saist\u012b\u0161anos ar im\u016bnkompleksiem uz oligodendroc\u012btu membr\u0101n\u0101m<\/li>\n\n\n\n<li><strong>C3aR <\/strong>un<strong> C5aR1 (CD88)<\/strong><br>Anafilatoks\u012bna receptori uz mikroglijas\/makrof\u0101giem \u2192 Proiekaisuma aktiv\u0101cija<\/li>\n\n\n\n<li><strong>Komplementa regulatori oligodendroc\u012btos<\/strong><br>CR1 (CD35), MCP (CD46), HRF (CD59) ir v\u0101ji izteikti oligodendroc\u012btos, t\u0101p\u0113c tie ir jut\u012bg\u0101ki pret komplementa boj\u0101jumiem nek\u0101, piem\u0113ram, astroc\u012bti.<\/li>\n<\/ul>\n\n\n\n<h1 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Histopathologie_und_ZNS-Lasionsmuster\"><\/span>Histopatolo\u0123ija un CNS boj\u0101jumu modelis<span class=\"ez-toc-section-end\"><\/span><\/h1>\n\n\n\n<p>MOGAD boj\u0101jumi histopatolo\u0123iski b\u016btiski at\u0161\u0137iras no MS un NMOSD:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Perivenoza demieliniz\u0101cija<\/strong><br>Boj\u0101jumi veidojas koncentr\u0113ti ap mazaj\u0101m v\u0113n\u0101m (perivenozi), nevis periaksi\u0101li k\u0101 MS gad\u012bjum\u0101. MRI nav MS rakstur\u012bg\u0101s \u201acentr\u0101lo v\u0113nu paz\u012bmes\u2018.<\/li>\n\n\n\n<li><strong>CD4+ T \u0161\u016bnu infiltr\u0101ts<\/strong><br>Domin\u0113 CD4+ T \u0161\u016bnas un makrof\u0101gi, maz\u0101k neitrofilu un gandr\u012bz nav eozinof\u012blo granuloc\u012btu (at\u0161\u0137ir\u012bb\u0101 no AQP4+ NMOSD).<\/li>\n\n\n\n<li><strong>Oligodendroc\u012btu boj\u0101jumi<\/strong> (prim\u0101rais)<br>At\u0161\u0137ir\u012bb\u0101 no NMOSD, kur galvenok\u0101rt tiek boj\u0101ti astroc\u012bti, MOGAD rakstur\u012bga oligodendroc\u012btu de\u0123ener\u0101cija.<\/li>\n\n\n\n<li><strong>C9neo nogulsn\u0113\u0161an\u0101s<\/strong><br>MAC (termin\u0101l\u0101 komplementa kompleksa) noteik\u0161ana boj\u0101jumos, lai gan v\u0101j\u0101ka nek\u0101 NMOSD gad\u012bjum\u0101.<\/li>\n\n\n\n<li><strong>Relat\u012bv\u0101 aksonu saglab\u0101\u0161ana<\/strong><br>Ak\u016btu l\u0113kmju gad\u012bjum\u0101 aksonu boj\u0101jumi bie\u017ei vien nav tik smagi k\u0101 MS gad\u012bjum\u0101, kas izskaidro bie\u017ei vien labo kl\u012bnisko atvese\u013co\u0161anos.<\/li>\n\n\n\n<li><strong>Kortik\u0101lie boj\u0101jumi<\/strong><br>Leptomeninge\u0101ls iekaisums un garozas demieliniz\u0101cija (izplat\u012bta ADEM variant\u0101).<\/li>\n<\/ul>\n\n\n\n<h1 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Klinische_Manifestationen_und_Phanotypen\"><\/span>Kl\u012bnisk\u0101s izpausmes un fenotipi<span class=\"ez-toc-section-end\"><\/span><\/h1>\n\n\n\n<p>MOGAD ir kl\u012bniski neviendab\u012bga. Svar\u012bgi fenotipi:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><td><strong>Fenotips<\/strong><\/td><td><strong>Bie\u017eums<\/strong><\/td><td><strong>Kl\u012bnisk\u0101s paz\u012bmes<\/strong><\/td><td><strong>MRI specialit\u0101tes<\/strong><\/td><\/tr><\/thead><tbody><tr><td>Redzes nerva neir\u012bts (ON)<\/td><td>Visbie\u017e\u0101k sastopamie (aptuveni 50%)<\/td><td>Bie\u017ei abpus\u0113js, redzes zudums, retrobulb\u0101rs, s\u0101p\u012bgas acu kust\u012bbas. acu kust\u012bbas<\/td><td>Ilgsto\u0161a redzes nerva iesaist\u012b\u0161ana, perinerv\u0101l\u0101 kontrastvielas uzkr\u0101\u0161an\u0101s<\/td><\/tr><tr><td>\u0160\u0137\u0113rsvirziena miel\u012bts<\/td><td>Aptuveni 30%<\/td><td>Longitudin\u0101lais miel\u012bts (LETM), ju\u0161anas\/motorikas, ur\u012bnp\u016b\u0161\u013ca darb\u012bbas trauc\u0113jumi<\/td><td>Gareniskie T2 boj\u0101jumi, H2 sindroms (\u201al\u0113cveida\u2018)<\/td><\/tr><tr><td>ADEM<\/td><td>Visbie\u017e\u0101k sastopam\u0101 izpausme b\u0113rniem<\/td><td>Encefalop\u0101tija, polifok\u0101ls neirolo\u0123isks defic\u012bts defic\u012bts<\/td><td>Divpus\u0113ji, liela apjoma T2 boj\u0101jumi, ar\u012b baz\u0101lie gangliji<\/td><\/tr><tr><td>Smadze\u0146u stumbra encefal\u012bts<\/td><td>Aptuveni 15%<\/td><td>Diplopija, ataksija, area postrema sindroms (\u017eagas, vem\u0161ana)<\/td><td>Smadze\u0146u stumbra \/ smadzen\u012b\u0161u T2 boj\u0101jumi<\/td><\/tr><tr><td>Kortik\u0101lais encefal\u012bts<\/td><td>Ret\u0101k<\/td><td>Epilepsijas l\u0113kmes, apjukums<\/td><td>Kortik\u0101l\u0101s FLAIR signaliz\u0101cijas izmai\u0146as<\/td><\/tr><tr><td>CRION<\/td><td>Ret\u0101k<\/td><td>Hronisks recidiv\u0113jo\u0161s iekaisums. redzes nerva neirop\u0101tija<\/td><td>Notur\u012bgs redzes nerva boj\u0101jums<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h1 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Diagnostik\"><\/span>Diagnostika<span class=\"ez-toc-section-end\"><\/span><\/h1>\n\n\n\n<p>Diagnostikas krit\u0113riji (Banwell et al, <em>Lancet Neurology<\/em> 2023): <\/p>\n\n\n\n<p>(1) MOG-IgG noteik\u0161ana serum\u0101 vai cerebrospin\u0101laj\u0101 \u0161\u0137idrum\u0101, izmantojot \u0161\u016bnu anal\u012bzi (CBA)<br>(2) atbilsto\u0161s kl\u012bniskais fenotips<br>(3) Alternat\u012bvu diagno\u017eu izsl\u0113g\u0161ana.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>\u0160\u016bnu imunofluorescences tests (CBA)<\/strong><br>ar dabiski saloc\u012btu, ar membr\u0101nu saist\u012btu MOG (HEK293 \u0161\u016bnas, transfic\u0113tas ar cilv\u0113ka MOG); nosaka no konform\u0101cijas atkar\u012bgus epitopus.<\/li>\n\n\n\n<li><strong>ELISA un l\u012bnijveida\/str\u0113me\u0146u blots<\/strong><br>Neuzticams attiec\u012bb\u0101 uz MOGAD, jo tiek atpaz\u012bti line\u0101ri epitopi.<\/li>\n\n\n\n<li><strong>IgG apak\u0161klases<\/strong><br>Galvenok\u0101rt IgG1; reiz\u0113m IgG2, IgG3, IgG4. Tikai IgG3 pozit\u012bvs rezult\u0101ts ir diagnostisks slazds (Jarius 2024).<\/li>\n\n\n\n<li><strong>Titru kin\u0113tika<\/strong><br>Past\u0101v\u012bgi augsts titrs korel\u0113 ar recid\u012bva risku; monof\u0101zisk\u0101 gait\u0101 bie\u017ei vien samazin\u0101s.<\/li>\n\n\n\n<li><strong>Alkoholiskie dz\u0113rieni<\/strong><br>Iesp\u0113jama pleocitoze; oligoklon\u0101l\u0101s joslas reti (&lt;10 %), intratek\u0101l\u0101 IgG sint\u0113ze reti<\/li>\n\n\n\n<li><strong>Biomar\u0137ieri<\/strong><br>sNfL (seruma neirofilamentu viegl\u0101 \u0137\u0113de) k\u0101 slim\u012bbas aktivit\u0101tes mar\u0137ieris; sGFAP (gli\u0101lais fibril\u0101rais sk\u0101bais prote\u012bns) k\u0101 astroc\u012btu iesaist\u012b\u0161an\u0101s mar\u0137ieris.<\/li>\n<\/ul>\n\n\n\n<h1 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Therapeutische_Strategien\"><\/span>Terapeitisk\u0101s strat\u0113\u0123ijas<span class=\"ez-toc-section-end\"><\/span><\/h1>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Akuttherapie_Schubbehandlung\"><\/span>Ak\u016bta terapija (recid\u012bva \u0101rst\u0113\u0161ana)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>MOGAD recid\u012bva standarta \u0101rst\u0113\u0161ana:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Lielas devas <em>Metilprednizolons<\/em> (HDMP)<\/strong><br>1000 mg i.v. dien\u0101 5 dienas - pirm\u0101 l\u012bnija<\/li>\n\n\n\n<li><em><strong>Plazmafer\u0113ze \/ imunoadsorbcija<\/strong><\/em><br>Nepietiekamas HDMP atbildes reakcijas gad\u012bjum\u0101; MOG-IgG iz\u0146em\u0161ana no plazmas; 5-7 cikli (retrospekt\u012bvie dati liecina par efektivit\u0101ti aptuveni 50-70% gad\u012bjumu).<\/li>\n\n\n\n<li><strong><em>Intravenozi ievad\u0101mi im\u016bnglobul\u012bni<\/em> (IVIG)<\/strong><br>2 g\/kg 5 dienu laik\u0101; ja nav atbildes reakcijas uz HDMP un k\u0101 iesp\u0113ja p\u0113c plazmafer\u0113zes; iesp\u0113jams, efekt\u012bva, pateicoties FcRn pies\u0101tin\u0101\u0161anai un Fc\u03b3R konkurencei.<\/li>\n\n\n\n<li><strong>Kortikostero\u012bdu lieto\u0161anas p\u0101rtrauk\u0161ana<\/strong><br>\u012apa\u0161i svar\u012bgi MOGAD (bie\u017ea atkar\u012bba no stero\u012bdiem) gad\u012bjum\u0101 - strauja samazin\u0101\u0161ana var izrais\u012bt atgrie\u0161an\u0101s epizodes.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Prophylaktische_Langzeittherapie\"><\/span>Profilaktiska ilgtermi\u0146a terapija<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>(nav re\u0123istr\u0113ts, nav at\u013cauta prepar\u0101ta - statuss 2026)<\/p>\n\n\n\n<p>Ilgsto\u0161as terapijas indik\u0101cija ir individu\u0101la - ne visiem pacientiem t\u0101 ir nepiecie\u0161ama. Faktori: recid\u012bvu bie\u017eums, recid\u012bvu smagums, notur\u012bgi MOG-IgG titri, fenotipiski riska faktori.<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><td><strong>Viela<\/strong><\/td><td><strong>Darb\u012bbas meh\u0101nisms<\/strong><\/td><td><strong>Datu situ\u0101cija<\/strong><\/td><td><strong>Pier\u0101d\u012bjumu l\u012bmenis<\/strong><\/td><\/tr><\/thead><tbody><tr><td>Azatiopr\u012bns<\/td><td>Pur\u012bnu sint\u0113zes blok\u0101de (atkar\u012bga no TPMT); kav\u0113 T un B \u0161\u016bnu prolifer\u0101ciju.<\/td><td>Retrospekt\u012bvie p\u0113t\u012bjumi; valsts m\u0113roga RCT turpin\u0101s (Francija, TOMATO p\u0113t\u012bjums).<\/td><td>IIb-III (\u0101rpus z\u0101\u013cu saraksta)<\/td><\/tr><tr><td>Mikofenol\u0101ta mofetils (MMF)<\/td><td>Inoz\u012bna monofosf\u0101ta dehidrogen\u0101zes inhibitors; inhib\u0113 limfoc\u012btu prolifer\u0101ciju.<\/td><td>Gad\u012bjumu s\u0113rija; iesp\u0113jams, efekt\u012bva, maz\u0101ka recid\u012bva profilakse nek\u0101 rituksimabam<\/td><td>III (\u0101rpus z\u0101\u013cu saraksta)<\/td><\/tr><tr><td>Rituksimabs<\/td><td>Anti-CD20 \u2192 B \u0161\u016bnu deplecija; kav\u0113 MOG-IgG veido\u0161anos<\/td><td>Liel\u0101k\u0101 retrospekt\u012bv\u0101 kohorta; efekt\u012bva, bet ne visiem; paaugstin\u0101ts infekcijas risks.<\/td><td>IIb (\u0101rpusre\u0123istr\u0113ta)<\/td><\/tr><tr><td>Tocilizumabs<\/td><td>Anti-IL-6R\u03b1 (iv); blo\u0137\u0113 IL-6 signaliz\u0101cijas ce\u013cu (JAK\/STAT3); inhib\u0113 Th17\/plazmas \u0161\u016bnas.<\/td><td>Pozit\u012bvi retrospekt\u012bvie dati; pozit\u012bvi RCT rezult\u0101ti NMOSD (TANGO)<\/td><td>IIb (\u0101rpusre\u0123istr\u0113ta)<\/td><\/tr><tr><td>IVIG (intravenoz\u0101\/ zem\u0101das)<\/td><td>Fc receptoru pies\u0101tin\u0101jums; MOG-IgG neitraliz\u0101cija; FcRn pies\u0101tin\u0101jums<\/td><td>Retrospekt\u012bvie dati ir pozit\u012bvi; iesp\u0113ja attiec\u012bb\u0101 uz augl\u012bbu, gr\u016btniec\u012bbu, infekciju<\/td><td>IIb (\u0101rpusre\u0123istr\u0113ta)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Klinische_Studien_%E2%80%93_2024%E2%80%932026\"><\/span>Kl\u012bniskie p\u0113t\u012bjumi - 2024-2026<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Pirmo reizi tiek veikti vair\u0101ki randomiz\u0113ti, placebo kontrol\u0113ti 3. f\u0101zes p\u0113t\u012bjumi par MOGAD, kas, k\u0101 paredzams, sniegs I klases pier\u0101d\u012bjumus:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><td><strong>P\u0113t\u012bjums<\/strong><\/td><td><strong>Viela<\/strong><\/td><td><strong>Meh\u0101nisms<\/strong><\/td><td><strong>M\u0113r\u0137a grupa<\/strong><\/td><td><strong>Statuss<\/strong><\/td><\/tr><\/thead><tbody><tr><td>cosMOG<\/td><td>Rozanoliksizumabs (UCB7665)<\/td><td>Anti-FcRn IgG4-mAb: blo\u0137\u0113 IgG p\u0101rstr\u0101di \u2192 pa\u0101trina IgG no\u0101rd\u012b\u0161anos, pazemina MOG IgG titru ~50 %<\/td><td>Pieaugu\u0161ie (\u2265 18 gadi), recid\u012bvs, \u2265 1 recid\u012bvs\/12 m\u0113ne\u0161u laik\u0101<\/td><td>3. f\u0101ze, starptautisks; pirmais MOGAD 3. f\u0101zes p\u0113t\u012bjums.<\/td><\/tr><tr><td>METEOROID<\/td><td>Satralizumabs (anti-IL-6R sc.)<\/td><td>Anti-IL-6R (zem\u0101das); inhib\u0113 JAK\/STAT3 \u2192 Th17 diferenci\u0101cija, B \u0161\u016bnu nobrie\u0161ana, IgG ra\u017eo\u0161ana<\/td><td>Pieaugu\u0161ie + pusaud\u017ei (\u2265 12 gadi); recid\u012bvs, pirms kura bijis \u2265 1 recid\u012bvs<\/td><td>3. posms, starptautisks, turpin\u0101s<\/td><\/tr><tr><td>TOMATO<\/td><td>Azatiopr\u012bns<\/td><td>Pur\u012bnu sint\u0113zes inhib\u012bcija; pla\u0161i im\u016bnsupres\u012bvs l\u012bdzeklis<\/td><td>Francijas daudzcentru p\u0113t\u012bjums; pieaugu\u0161ie ar MOGAD<\/td><td>Valsts RCT, 3. f\u0101ze<\/td><\/tr><tr><td>MOGwAI<\/td><td>Nav nor\u0101d\u012bts (nov\u0113ro\u0161ana)<\/td><td>Biomar\u0137ieru p\u0113t\u012bjums: MOG-IgG titra, sNfL, sGFAP, sCD83 k\u0101 progres\u0113\u0161anas mar\u0137ieru valid\u0101cija<\/td><td>Starptautisks kohortas p\u0113t\u012bjums<\/td><td>Notiek<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Neue_und_zukunftige_Therapiekonzepte\"><\/span>Jaunas un n\u0101kotnes terapijas koncepcijas<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Pamatojoties uz p\u0113d\u0113jo gadu molekul\u0101rajiem atkl\u0101jumiem, tiek apspriestas \u0161\u0101das pieejas MOGAD:<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"BTK-Inhibitoren_Bruton-Tyrosin-Kinase\"><\/span>BTK inhibitori (Brutona tiroz\u012bnkin\u0101ze)<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>BTK ir centr\u0101l\u0101 B \u0161\u016bnu receptoru signaliz\u0101cijas kask\u0101des (PI3K\/AKT\/MAPK) kin\u0101ze. <strong><em>Tolebrutinibs<\/em><\/strong> un citi BTK inhibitori tiek izmantoti MS un NMOSD p\u0113t\u012bjumos; MOGAD v\u0113l tiek veikti kl\u012bniskie p\u0113t\u012bjumi. Peror\u0101la lieto\u0161ana b\u016btu priek\u0161roc\u012bba. B \u0161\u016bnu aktiv\u0101cijas un mielo\u012bdo \u0161\u016bnu (mikroglia-BTK) inhib\u0113\u0161ana.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Toleranzinduktion_MOG-Tolerisierung\"><\/span>Tolerances izrais\u012b\u0161ana (MOG toler\u0113\u0161ana)<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Antig\u0113nam specifiskas tolerances indukcija (piem\u0113ram, izmantojot MOG pept\u012bdus vai uz nanoda\u013ci\u0146\u0101m balst\u012btas pieejas) ir daudzsolo\u0161a koncepcija. . <strong><em>Guthy-Jackson labdar\u012bbas fonds<\/em><\/strong> Veicina p\u0113t\u012bjumus par \u0101rstniecisk\u0101m pieej\u0101m. Priek\u0161roc\u012bba: nav visp\u0101r\u0113jas im\u016bnsupresijas, <strong>MOG autoreaktivit\u0101tes selekt\u012bva nov\u0113r\u0161ana<\/strong>.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Komplementinhibitoren\"><\/span>Komplementa inhibitori<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>T\u0101 k\u0101 komplementa aktiv\u0101cija (C3a, C5a, MAC) ir nosak\u0101ma MOGAD boj\u0101jumos, b\u016btu nepiecie\u0161ams <strong><em>Ekulizumabs<\/em> (Anti-C5)<\/strong> vai C3 inhibitors teor\u0113tiski ir efekt\u012bvs. Tom\u0113r, t\u0101 k\u0101 MAC komplekss (C5b-9) MOGAD veidojas daudz maz\u0101k\u0101 m\u0113r\u0101 nek\u0101 NMOSD (kur C5b-9). <em>Ekulizumabs<\/em> ir at\u013cauta), kl\u012bnisk\u0101 noz\u012bme ir neskaidra.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Anti-Neonatal-Fc-Rezeptor-Strategien\"><\/span>Strat\u0113\u0123ijas pret neonat\u0101lo Fc receptoru<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Papildus <em>Rozanoliksizumabs<\/em> ar\u012b <strong><em>Efgartigimods<\/em><\/strong> (IgG-Fc fragments, kas konkur\u0113jo\u0161i blo\u0137\u0113 FcRn) cit\u0101m IgG medi\u0113t\u0101m slim\u012bb\u0101m. T\u0101 k\u0101 FcRn blok\u0101des patomeh\u0101nisms tie\u0161i pazemina MOG-IgG l\u012bmeni, \u0161\u012b ir \u012bpa\u0161i m\u0113r\u0137tiec\u012bga pieeja.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Autologe_hamatopoetische_Stammzelltransplantation_aHSCT\"><\/span>Autolog\u0101 hematopo\u0113tisko cilmes \u0161\u016bnu transplant\u0101cija (aHSCT)<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Smagas, refrakt\u0101ras slim\u012bbas gad\u012bjum\u0101 aHSCT ir potenci\u0101li \u0101rstnieciska koncepcija: dzi\u013ca im\u016bnoabl\u0101cija un im\u016bnsist\u0113mas atjauno\u0161ana var\u0113tu likvid\u0113t autoreakt\u012bvo T un B \u0161\u016bnu klonus. Pieejami \u013coti ierobe\u017eoti dati par MOGAD; izmanto tikai specializ\u0113tos centros.<\/p>\n\n\n\n<h1 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Biomarker_und_Verlaufsmonitoring\"><\/span>Biomar\u0137ieri un turpm\u0101k\u0101 uzraudz\u012bba<span class=\"ez-toc-section-end\"><\/span><\/h1>\n\n\n\n<p>Pa\u0161reiz\u0113jo p\u0113t\u012bjumu m\u0113r\u0137is ir pie\u0146emt uz biomar\u0137ieriem balst\u012btus l\u0113mumus par terapiju:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>MOG-IgG titrs (serum\u0101)<\/strong><br>Past\u0101v\u012bba korel\u0113 ar recid\u012bva risku; monof\u0101ziskas slim\u012bbas gad\u012bjum\u0101 bie\u017ei vien spont\u0101ns titra kritums; l\u012bdznoteico\u0161ais faktors ir l\u0113mums par terapiju.<\/li>\n\n\n\n<li><strong>Seruma neirofilamentu gaisma (sNfL)<\/strong><br>Aksonu boj\u0101juma mar\u0137ieris; paaugstin\u0101ts recid\u012bva laik\u0101; normaliz\u0113jas k\u0101 terapijas atbildes reakcijas mar\u0137ieris.<\/li>\n\n\n\n<li><strong>GFAP serum\u0101 (sGFAP)<\/strong><br>Astroc\u012btu aktiv\u0101cija; zem\u0101ka MOGAD nek\u0101 NMOSD; var sniegt papildu inform\u0101ciju.<\/li>\n\n\n\n<li><strong>sCD83<\/strong><br>Jauns kandid\u0101tbiomar\u0137ieris (tiek valid\u0113ts); iesp\u0113jams, dendr\u012btisko \u0161\u016bnu aktiviz\u0101cijas un im\u016bn\u0101s aktivit\u0101tes mar\u0137ieris.<\/li>\n\n\n\n<li><strong>Cerebrospin\u0101l\u0101 \u0161\u0137idruma \u0161\u016bnu skaits un olbaltumvielas<\/strong><br>Pleocitoze vilkmes epizo\u017eu laik\u0101; normaliz\u0113jas p\u0113c terapijas<\/li>\n<\/ul>\n\n\n\n<h1 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Prognose_und_Besonderheiten\"><\/span>Prognozes un \u012bpa\u0161as funkcijas<span class=\"ez-toc-section-end\"><\/span><\/h1>\n\n\n\n<p>Sal\u012bdzinot ar AQP4+ NMOSD, MOGAD ir tendence uzr\u0101d\u012bt <strong>Labv\u0113l\u012bg\u0101ka prognoze<\/strong>, jo \u012bpa\u0161i lab\u0101ka redzes atjauno\u0161an\u0101s p\u0113c ON. Tom\u0113r svar\u012bgi ir \u0161\u0101di aspekti:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Vienf\u0101\u017eu progresija<\/strong><br>Aptuveni 50% pacientu; bie\u017ei vien titrs samazin\u0101s spont\u0101ni; ilgsto\u0161a terapija var neb\u016bt nepiecie\u0161ama.<\/li>\n\n\n\n<li><strong>Vilces formas progresija<\/strong><br>Aptuveni 50%; liel\u0101ks titrs saglab\u0101jas; iesp\u0113jama kumulat\u012bvas invalidit\u0101tes veido\u0161an\u0101s, bet l\u0113n\u0101k nek\u0101 NMOSD.<\/li>\n\n\n\n<li><strong>Nav progres\u012bva kursa<\/strong><br>At\u0161\u0137ir\u012bb\u0101 no MS nav aprakst\u012bta pak\u0101peniska progres\u0113\u0161ana bez recid\u012bviem.<\/li>\n\n\n\n<li><strong>Jut\u012bba pret stero\u012bdiem un atkar\u012bba no stero\u012bdiem<\/strong><br>Tom\u0113r daudzi pacienti \u013coti labi rea\u0123\u0113 uz kortikostero\u012bdiem: strauja to lieto\u0161anas p\u0101rtrauk\u0161ana bie\u017ei izraisa recid\u012bvus.<\/li>\n\n\n\n<li><strong>\u012apa\u0161a pediatrijas iez\u012bme<\/strong><br>ADEM visbie\u017e\u0101k\u0101 s\u0101kotn\u0113j\u0101 izpausme b\u0113rniem (&lt;10 gadi); prognoze bie\u017ei ir laba, bet j\u0101\u0146em v\u0113r\u0101 atk\u0101rto\u0161an\u0101s risks.<\/li>\n\n\n\n<li><strong>Gr\u016btniec\u012bba: pl\u0101ni dati<\/strong><br>Kopum\u0101 nav paaugstin\u0101ta recid\u012bva riska gr\u016btniec\u012bbas laik\u0101, bet p\u0113cdzemd\u012bbu period\u0101 tas var\u0113tu b\u016bt riska faktors (l\u012bdz\u012bgi k\u0101 MS).<\/li>\n<\/ul>\n\n\n\n<h1 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Zusammenfassung_und_Ausblick\"><\/span>Kopsavilkums un perspekt\u012bvas<span class=\"ez-toc-section-end\"><\/span><\/h1>\n\n\n\n<p>MOGAD ir neatkar\u012bga, antivielu medi\u0113ta autoim\u016bna CNS slim\u012bba, ko raksturo \u0161\u0101das galven\u0101s paz\u012bmes:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>MOG prote\u012bns oligodendroc\u012btu un miel\u012bna apvalku \u0101rpus\u0113 ir m\u0113r\u0137a antig\u0113ns.<\/li>\n\n\n\n<li>Patog\u0113n\u0101s MOG-IgG1 autoantivielas boj\u0101 miel\u012bnu, izmantojot divus paral\u0113lus efektoru ce\u013cus: komplementa aktiv\u0101ciju (CDC, aptuveni 50%) un Fc\u03b3R saist\u012b\u0161anos (ADCC\/ADCP, aptuveni 50%).<\/li>\n\n\n\n<li>Turkl\u0101t antivielas pastiprina T-\u0161\u016bnu aktiv\u0101ciju, izmantojot Fc\u03b3R meh\u0101nismus.<\/li>\n\n\n\n<li>IL-6\/JAK\/STAT3 signaliz\u0101cijas ce\u013c\u0161 veicina Th17 diferenci\u0101ciju un plazmatisko \u0161\u016bnu nobrie\u0161anu un ir galvenais terapeitiskais m\u0113r\u0137is.<\/li>\n\n\n\n<li>Pa\u0161laik nav apstiprin\u0101tu terapiju (no 2026. gada febru\u0101ra); notiek pirm\u0101s 3. f\u0101zes RCT (cosMOG ar rozanoliksizumabu, METEOROID ar satralizumabu).<\/li>\n\n\n\n<li>Terapija virz\u0101s uz riska nov\u0113rt\u0113\u0161anai piel\u0101got\u0101m strat\u0113\u0123ij\u0101m, kas balst\u012btas uz biomar\u0137ieriem.<\/li>\n<\/ul>\n\n\n\n<p>Svar\u012bg\u0101kais p\u0113d\u0113jo gadu p\u0113tnieciskais progress ir bijis prec\u012bza efektoru meh\u0101nismu (komplementa un FcR ce\u013ca) dekod\u0113\u0161ana, ko veiku\u0161as t\u0101das p\u0113tniec\u012bbas grupas k\u0101, piem\u0113ram, p\u0113tnieku grupa no <strong>Meinls, Maders, Kavakami (LMU Minhene)<\/strong>, kam ir tie\u0161a ietekme uz terapijas att\u012bst\u012bbu: Optim\u0101lai terapeitiskajai pieejai ir j\u0101v\u0113r\u0161as pret IgG ra\u017eo\u0161anu (anti-CD20, FcRn inhibitori), k\u0101 ar\u012b pret efektoru meh\u0101nismiem (komplements, Fc\u03b3R) un Th17\/IL-6 asi.<\/p>\n\n\n\n<p>Tolerances indukcijas strat\u0113\u0123ijas un BTK inhibitori ir meh\u0101niski pamatoti n\u0101kotnes terapeitiskie principi, kurus, iesp\u0113jams, kl\u012bniski izm\u0113\u0123in\u0101s tuv\u0101kajos gados.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Atherischer_Ole_%E2%80%93_Wirkstoffe_nach_Signalwegen_geordnet\"><\/span>\u0112terisk\u0101s e\u013c\u013cas - akt\u012bv\u0101s sast\u0101vda\u013cas, kas sak\u0101rtotas p\u0113c signaliz\u0101cijas ce\u013ciem<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Akt\u012bv\u0101s vielas var sagrup\u0113t atbilsto\u0161i to iedarb\u012bbas punktiem MOGAD patofiziolo\u0123ij\u0101. Tas ir \u013coti svar\u012bgi, jo MOGAD ir tr\u012bs galven\u0101s asis: <\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Th17\/IL-6<\/strong><\/li>\n\n\n\n<li><strong>Komplementa sist\u0113ma\/oligodendroc\u012btu aizsardz\u012bba<\/strong><\/li>\n\n\n\n<li><strong>Remieliniz\u0101cija\/OPC diferenci\u0101cija<\/strong>.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Weihrauch_Boswellia_serrata_%E2%80%93_AKBA_und_Incensolacetat\"><\/span>Frankincense (Boswellia serrata) - AKBA un incensola acet\u0101ts<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Saska\u0146\u0101 ar BCP datiem \u0161is ir zin\u0101tniski vispamatot\u0101kais MOGAD kandid\u0101ts, un t\u0101 iedarb\u012bbas spektrs ir \u0101rk\u0101rt\u0113js.<\/p>\n\n\n\n<p><strong>AKBA (3-O-acetil-11-keto-\u03b2-bosve\u013csk\u0101be)<\/strong> ir galvenais akt\u012bvais princips. AKBA piem\u012bt daudzveid\u012bga fiziolo\u0123iska iedarb\u012bba, tostarp pretinfekcijas, pretv\u0113\u017ea un antioksidanta iedarb\u012bba, k\u0101 ar\u012b pier\u0101d\u012bta neiroprotekt\u012bva iedarb\u012bba. T\u0101 veicina nervu atjauno\u0161anos un re\u0123ener\u0101ciju, aizsarg\u0101 pret smadze\u0146u i\u0161\u0113miskiem boj\u0101jumiem, kav\u0113 neiroinflam\u0101ciju un uzlabo atmi\u0146as trauc\u0113jumus. <a href=\"https:\/\/www.ean.org\/research\/resources\/neurology-updates\/detail\/complement-dependent-and-independent-pathomechanisms-of-myelin-oligodendrocyte-glycoprotein-mog-abs-implications-for-therapeutic-strategies-in-mog-antibody-associated-disease-mogad\" target=\"_blank\" rel=\"noreferrer noopener\">Eiropas Neirolo\u0123ijas akad\u0113mija<\/a><\/p>\n\n\n\n<p><strong>AKBA inhib\u0113 STAT3<\/strong> devas atkar\u012bba, kas ir galvenais meh\u0101nisms, jo STAT3 ir galvenais IL-6\/JAK signaliz\u0101cijas ce\u013ca transkripcijas faktors, kas veicina Th17 diferenci\u0101ciju un plazmatisko \u0161\u016bnu nobrie\u0161anu MOGAD. Turkl\u0101t AKBA aktiviz\u0113tais Nrf2\/HO-1 signaliz\u0101cijas ce\u013c\u0161 nodro\u0161ina virzienu oksidat\u012bvo boj\u0101jumu mazin\u0101\u0161anai, demieliniz\u0101cijas nov\u0113r\u0161anai un remieliniz\u0101cijas veicin\u0101\u0161anai. <a href=\"https:\/\/pubs.acs.org\/doi\/10.1021\/acs.nanolett.9b02220\" target=\"_blank\" rel=\"noreferrer noopener\">ACS publik\u0101cijas<\/a><\/p>\n\n\n\n<p>AKBA darbojas k\u0101 molekul\u0101rais sl\u0113dzis, kas blo\u0137\u0113 leikotri\u0113nu veido\u0161anos, alosteriski modul\u0113jot 5-LOX un 15-LOX, bet vienlaikus stimul\u0113 SPM (specializ\u0113to prorea\u0123\u0113jo\u0161o mediatoru) ra\u017eo\u0161anu. Tas akt\u012bvi novirza im\u016bnsist\u0113mas atbildes reakciju virzien\u0101 uz <strong>Iekaisuma iz\u0161\u0137ir\u0161ana<\/strong>, ne tikai to sl\u0101p\u0113\u0161ana. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/39133885\/\" target=\"_blank\" rel=\"noreferrer noopener\">PubMed<\/a><\/p>\n\n\n\n<p><strong>Incensola acet\u0101ts<\/strong> (v\u012braka \u0113terisk\u0101s e\u013c\u013cas gaisto\u0161ais komponents, notiek BHS) aktiviz\u0113 TRPV3 kan\u0101lus neironos, k\u0101 ar\u012b PPAR-\u03b3 - v\u012braka komponenti var iev\u0113rojami samazin\u0101t IL-6, TNF-\u03b1 un GFAP (astroc\u012btu aktiv\u0101cijas mar\u0137ieris) smadzen\u0113s p\u0113c induc\u0113ta iekaisuma. <a href=\"https:\/\/www.neurology.org\/doi\/10.1212\/NXI.0000000000200293\" target=\"_blank\" rel=\"noreferrer noopener\">Neirolo\u0123ija<\/a><\/p>\n\n\n\n<p><strong>Svar\u012bga piez\u012bme par kvalit\u0101ti:<\/strong> Bosv\u0113lijas produktu kvalit\u0101te iev\u0113rojami at\u0161\u0137iras, da\u017eos produktos (piem\u0113ram, H15 Ayurmedica\u00ae) anal\u012bz\u0113s tika konstat\u0113ts tikai neliels daudzums rakstur\u012bgo bosveliju sk\u0101bju (0,31 mg AKBA). Turpret\u012b t\u0101dos produktos k\u0101 BOSWELLIASAN\u00ae (7,51 mg) un Sallaki\u00ae tabletes (7,88 mg) tika konstat\u0113ts iev\u0113rojams AKBA daudzums un attiec\u012bgi sp\u0113c\u012bga farmakolo\u0123isk\u0101 iedarb\u012bba. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/34358086\/\" target=\"_blank\" rel=\"noreferrer noopener\">Bosve\u013csk\u0101bes satura anal\u012bze un ar to saist\u012bt\u0101s farmakolo\u0123isk\u0101s aktivit\u0101tes l\u012bdzek\u013cos, kas balst\u012bti uz v\u012braku un kas modul\u0113 iekaisumu<\/a> un <a href=\"https:\/\/www.frontiersin.org\/journals\/immunology\/articles\/10.3389\/fimmu.2025.1530977\/full\" target=\"_blank\" rel=\"noreferrer noopener\">Robe\u017eas<\/a>.<\/p>\n\n\n\n<p>DoTERRA produkts <strong><a href=\"https:\/\/media.doterra.com\/us\/en\/pips\/frankincense-boswellic-acid-complex.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Frankincense Bosve\u013csk\u0101bes komplekss<\/a><\/strong> satur 37,5 mg AKBA*<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Therapeutisch_relevante_AKBA-Zieldosen\"><\/span>Terapeitiski atbilsto\u0161as AKBA m\u0113r\u0137a devas<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Kl\u012bniskajos un pirmskl\u012bniskajos p\u0113t\u012bjumos ieg\u016bta \u0161\u0101da aina:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Pieteikuma m\u0113r\u0137is<\/th><th>AKBA dienas deva<\/th><th>Avots:<\/th><\/tr><\/thead><tbody><tr><td>Pretiekaisuma l\u012bdzek\u013ci (visp\u0101r\u012bgi)<\/td><td>100-200 mg<\/td><td>Cilv\u0113ka p\u0113t\u012bjumi loc\u012btava\/ zarnas<\/td><\/tr><tr><td>NF-\u03baB \/ STAT3 inhib\u012bcija (neiroinflammation)<\/td><td>200-400 mg<\/td><td>Dz\u012bvnieku mode\u013ci, \u0161\u016bnu kult\u016bras<\/td><\/tr><tr><td>Optim\u0101la iedarb\u012bba uz CNS (barjeras \u0161\u0137\u0113rso\u0161ana)<\/td><td>200-300 mg<\/td><td>Eksperiment\u0101lie dati<\/td><\/tr><tr><td>Augst\u0101ka labi panesama dienas deva<\/td><td>400-600 mg<\/td><td>Tolerances p\u0113t\u012bjumi<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Umrechnung_auf_375_mg_AKBA_jeKapsel\"><\/span>Konvert\u0113t uz 37,5 mg AKBA vien\u0101 kapsul\u0101<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>AKBA m\u0113r\u0137a dienas deva<\/th><th>Vien\u012bbas\/dien\u0101<\/th><th>Praktisk\u0101 sh\u0113ma<\/th><\/tr><\/thead><tbody><tr><td>150 mg<\/td><td>4 vien\u012bbas<\/td><td>2 \u00d7 no r\u012bta + 2 \u00d7 vakar\u0101<\/td><\/tr><tr><td>200 mg<\/td><td><strong>5-6 vien\u012bbas<\/strong><\/td><td>3 \u00d7 no r\u012bta + 2-3 \u00d7 vakar\u0101<\/td><\/tr><tr><td>300 mg<\/td><td>8 vien\u012bbas<\/td><td>4 \u00d7 no r\u012bta + 4 \u00d7 vakar\u0101<\/td><\/tr><tr><td>400 mg<\/td><td>10-11 vien\u012bbas<\/td><td>3 \u00d7 3-4 vien\u012bbas dien\u0101<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Ieteicamais ieraksts:<\/strong> <strong>4 vien\u012bbas dien\u0101 (= 150 mg AKBA)<\/strong>, sadal\u012bta 2 d\u0101van\u0101s.<\/p>\n\n\n\n<p>P\u0113c 2 ned\u0113\u013c\u0101m - ja labi panes - palieliniet devu l\u012bdz 6 vien\u012bb\u0101m (= 225 mg).<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Wichtige_Einnahmehinweise\"><\/span>Svar\u012bgi uz\u0146em\u0161anas nor\u0101d\u012bjumi<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>Tauki ir \u013coti svar\u012bgi:<\/strong> AKBA ir \u013coti lipof\u012bla, un <strong>Biopieejam\u012bba palielin\u0101s 2-3 reizes<\/strong>, ja lieto kop\u0101 ar treknu malt\u012bti. Ide\u0101li piem\u0113rota ir ol\u012bve\u013c\u013ca, avokado vai pamat\u0113diens. Lieto\u0161ana tuk\u0161\u0101 d\u016b\u0161\u0101 iev\u0113rojami samazina uzs\u016bk\u0161anos.<\/p>\n\n\n\n<p><strong>Laiks:<\/strong> AKBA pussabruk\u0161anas periods ir aptuveni 6 stundas, t\u0101p\u0113c <strong>2-3 devas dien\u0101<\/strong> Tas ir lietder\u012bg\u0101k nek\u0101 vienreiz\u0113ja deva, lai uztur\u0113tu vienm\u0113r\u012bgu efektivit\u0101ti.<\/p>\n\n\n\n<p><strong>Kombin\u0101cija ar BCP:<\/strong> AKBA (STAT3\/NF-\u03baB ass) un BCP (CB2\/Th17 ass) iedarbojas uz da\u017e\u0101diem MOGAD signaliz\u0101cijas ce\u013ciem un darbojas siner\u0123iski. Nav zin\u0101ma farmakolo\u0123isk\u0101 mijiedarb\u012bba.<\/p>\n\n\n\n<p><strong>Ku\u0146\u0123a panesam\u012bba:<\/strong> Bosv\u0113lija parasti tiek \u013coti labi panesta. Neliels ku\u0146\u0123a kairin\u0101jums reti rodas, lietojot liel\u0101kas devas. T\u0101p\u0113c vienm\u0113r lietojiet kop\u0101 ar malt\u012bti vai, ja nepiecie\u0161ams, \u012bslaic\u012bgi samaziniet devu.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Schwarzer_Pfeffer_oral\"><\/span>Melnie pipari (iek\u0161\u0137\u012bgi)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Melno piparu e\u013c\u013cas galven\u0101 akt\u012bv\u0101 viela \u03b2-kariofil\u0113ns (BCP) (<em>Piper nigrum<\/em>) izraisa iekaisuma citok\u012bnu IL-6, TNF-\u03b1, IL-17, IFN-\u03b3 un Th17 (ROR-\u03b3t) un Th1 (T-bet) transkripcijas faktoru samazin\u0101\u0161anos, k\u0101 ar\u012b pretiekaisuma citok\u012bnu TGF-\u03b21, IL-10, IL-4 un Th2 (GATA3) un Treg (Foxp3) transkripcijas faktoru b\u016btisku palielin\u0101\u0161anos. \u0160ie efekti ir cie\u0161i saist\u012bti ar CB2 receptoru aktiviz\u0101ciju.<\/p>\n\n\n\n<p>CB2 receptori un remieliniz\u0101cija ir tie\u0161i meh\u0101niski saist\u012bti: CB2 agonisms veicina OPC nobrie\u0161anu - n\u0101kam\u0101s paaudzes CB2 agonists (Yhhu4952) iev\u0113rojami palielin\u0101ja miel\u012bna pamatprote\u012bna (MBP) ekspresiju un nobriedu\u0161u oligodendroc\u012btu \u012bpatsvaru kaulu \u0137ermen\u012b.<\/p>\n\n\n\n<p>Melno piparu deva: 20 ... 200 mg\/d - atbilst 20 tr.\/d - t\u0101p\u0113c vislab\u0101k lietot 7 trp. ik p\u0113c 8 stund\u0101m (lab\u0101k 5 trp. ik p\u0113c 6 stund\u0101m, lai paaugstin\u0101tu l\u012bmeni plazm\u0101) nes\u0113je\u013c\u013c\u0101 kapsul\u0101. K\u0101 lipofilu kop\u0101 ar \u0113dienu\/dz\u0113rienu ar augstu tauku saturu.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Schwarzer_Pfeffer_Inhalation\"><\/span>Melnie pipari (inhal\u0101cijai)<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Doz\u0113\u0161ana: dienas laik\u0101 ik p\u0113c 4 stund\u0101m ieelpojiet 3 tr. ik p\u0113c 4 stund\u0101m (pusperiods ir 2 - 4 stundas) uz apsild\u0101m\u0101 difuzora Liqui-Pad uz 20 min\u016bt\u0113m un p\u0113c katras dzi\u013cas ieelpas aizturiet elpu uz aptuveni 5 - 8 sekund\u0113m, nakt\u012b atst\u0101jiet difuzoru darbin\u0101mu telp\u0101, tie\u0161u ieelpo\u0161anu neveiciet.<\/p>\n\n\n\n<p>Melnajiem pipariem var b\u016bt stimul\u0113jo\u0161a iedarb\u012bba un tie var trauc\u0113t miegu. \u0160\u0101d\u0101 gad\u012bjum\u0101 nelietot nakt\u012b.<\/p>\n\n\n\n<p>Ja rodas elpce\u013cu kairin\u0101jums (sausums) vai galvass\u0101pes: Samaziniet devu vai palieliniet interv\u0101lus.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Copaiba-Ol_oral_%E2%80%93_NUR_doTERRA\"><\/span>Copaiba e\u013c\u013ca (iek\u0161\u0137\u012bgi) - TIKAI doTERRA<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>52,6 % BCP - atbilst 14,7 mg BCP\/kapi - t\u0101 k\u0101 BCP ir lipof\u012bls, vienm\u0113r lietojiet kop\u0101 ar \u0113dienu\/dz\u0113rienu ar augstu tauku saturu!<\/p>\n\n\n\n<p>Saska\u0146\u0101 ar kl\u012bnisk\u0101s dro\u0161\u012bbas p\u0113t\u012bjumiem, pamatojoties uz \u0137erme\u0146a svaru, tiek rekomend\u0113tas \u0161\u0101das devas:<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"MOGAD-spezifische_Dosierungstabelle_doTERRA_Copaiba_525_BCP\"><\/span>MOGAD specifiska doz\u0113\u0161anas tabula (doTERRA Copaiba 52,5 % BCP)<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>\u0136erme\u0146a svars<\/th><th><strong>Aizsardz\u012bba<\/strong> (0,4 mg\/kg)<\/th><th><strong>Akt\u012bv\u0101 vilkme<\/strong> (1,0 mg\/kg)<\/th><th><strong>Intens\u012bva terapija<\/strong> (1,5 mg\/kg)<\/th><\/tr><\/thead><tbody><tr><td><strong>50 kg<\/strong><\/td><td>20 mg = <strong>1-2 pilieni<\/strong><\/td><td>50 mg = <strong>3-4 pilieni<\/strong><\/td><td>75 mg = <strong>5 pilieni<\/strong><\/td><\/tr><tr><td><strong>60 kg<\/strong><\/td><td>24 mg = <strong>2 pilieni<\/strong><\/td><td>60 mg = <strong>4 pilieni<\/strong><\/td><td>90 mg = <strong>6 pilieni<\/strong><\/td><\/tr><tr><td><strong>70 kg<\/strong><\/td><td>28 mg = <strong>2 pilieni<\/strong><\/td><td>70 mg = <strong>5 pilieni<\/strong><\/td><td>105 mg = <strong>7 pilieni<\/strong><\/td><\/tr><tr><td><strong>80 kg<\/strong><\/td><td>32 mg = <strong>2 pilieni<\/strong><\/td><td>80 mg = <strong>5-6 pilieni<\/strong><\/td><td>120 mg = <strong>8 pilieni<\/strong><\/td><\/tr><tr><td><strong>90 kg<\/strong><\/td><td>36 mg = <strong>2-3 pilieni<\/strong><\/td><td>90 mg = <strong>6 pilieni<\/strong><\/td><td>135 mg = <strong>9 pilieni<\/strong><\/td><\/tr><tr><td><strong>100 kg<\/strong><\/td><td>40 mg = <strong>3 pilieni<\/strong><\/td><td>100 mg = <strong>7 pilieni<\/strong><\/td><td>150 mg = <strong>10 pilieni<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"MOGAD-Phasen-adaptierte_Dosierung\"><\/span>MOGAD f\u0101z\u0113m piel\u0101gota doz\u0113\u0161ana<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Phase_1_Akuter_Schub_erste_2%E2%80%934_Wochen\"><\/span><strong>1. f\u0101ze: ak\u016bts paasin\u0101jums (pirm\u0101s 2-4 ned\u0113\u013cas)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p><strong>M\u0113r\u0137is:<\/strong> Agres\u012bva Th17 nom\u0101k\u0161ana, IL-6 samazin\u0101\u0161ana<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Devas:<\/strong> 1,0-1,5 mg\/kg dien\u0101<\/li>\n\n\n\n<li><strong>Pie\u0161\u0137ir\u0161ana:<\/strong> 3 reizes dien\u0101 (optim\u0101li nep\u0101rtrauktai CB2 receptoru aktiviz\u0113\u0161anai)<\/li>\n\n\n\n<li><strong>Piem\u0113rs 70 kg:<\/strong> 5-7 pilieni dien\u0101, izklied\u0113jot pa 2+2+3 pilieniem.<\/li>\n\n\n\n<li><strong>Kombin\u0101cija:<\/strong> Ar AKBA (200-300 mg\/dien\u0101 STAT3 inhib\u0113\u0161anai) + augstas devas kortizona (standarta)<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Phase_2_Schubremission_Erhaltung_langfristig\"><\/span><strong>2. f\u0101ze: recid\u012bva remisija \/ uztur\u0113\u0161ana (ilgtermi\u0146a)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p><strong>M\u0113r\u0137is:<\/strong> Recid\u012bva profilakse, past\u0101v\u012bgs pretiekaisuma tonuss<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Devas:<\/strong> 0,4-0,7 mg\/kg dien\u0101<\/li>\n\n\n\n<li><strong>Pie\u0161\u0137ir\u0161ana:<\/strong> 2\u00d7 dien\u0101<\/li>\n\n\n\n<li><strong>Piem\u0113rs 70 kg:<\/strong> 2-3 pilieni dien\u0101, izklied\u0113jot k\u0101 1+2 vai 2+2 pilienus.<\/li>\n\n\n\n<li><strong>Kombin\u0101cija:<\/strong> Ar AKBA (150 mg\/dien\u0101) p\u0113c izv\u0113les<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Phase_3_Monophasischer_Verlauf_Titer_fallend\"><\/span><strong>3. f\u0101ze: monof\u0101zisks kurss (titra samazin\u0101\u0161an\u0101s)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p><strong>M\u0113r\u0137is:<\/strong> Neiroprotekcija, remieliniz\u0101cija<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Devas:<\/strong> 0,2-0,4 mg\/kg dien\u0101<\/li>\n\n\n\n<li><strong>Pie\u0161\u0137ir\u0161ana:<\/strong> 1-2\u00d7 dien\u0101<\/li>\n\n\n\n<li><strong>Piem\u0113rs 70 kg:<\/strong> 1-2 pilieni dien\u0101<\/li>\n\n\n\n<li><strong>Iesp\u0113jama l\u012bdzsvaro\u0161ana<\/strong> p\u0113c 6-12 m\u0113ne\u0161u stabilas seronegativit\u0101tes.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Quellen\"><\/span>Avoti<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Toksikolo\u0123ija (700 mg\/kg NOAEL)<\/strong><br><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/27358239\/\" target=\"_blank\" rel=\"noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/27358239\/<\/a><\/li>\n\n\n\n<li><strong>EAE modelis (2,5-5 mg\/kg efekt\u012bvi)<\/strong><br><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10377147\/\" target=\"_blank\" rel=\"noopener\">https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10377147\/<\/a><\/li>\n\n\n\n<li><strong>P\u0113t\u012bjums ar cilv\u0113kiem (100 mg dro\u0161s)<\/strong><br><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9104399\/\" target=\"_blank\" rel=\"noopener\">https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9104399\/<\/a><\/li>\n\n\n\n<li><strong>Kl\u012bniskais p\u0113t\u012bjums (126 mg\/dien\u0101)<\/strong><br><a href=\"https:\/\/accurateclinic.com\/accurate-education-terpenes-caryophyllene\/\" target=\"_blank\" rel=\"noopener\">https:\/\/accurateclinic.com\/accurate-education-terpenes-caryophyllene\/<\/a><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Copaiba-Ol_Inhalation\"><\/span>Kopaibas e\u013c\u013ca (inhal\u0101cijai)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Papildus melnajiem pipariem, kuru maksim\u0101lais saturs ir 38% BCP, daudz sp\u0113c\u012bg\u0101ka ir kopaibas e\u013c\u013ca, kuras maksim\u0101lais saturs ir 87% BCP, t\u0101p\u0113c t\u0101 ir lab\u0101k\u0101 izv\u0113le inhal\u0101cijai.<br>Difuzori parasti darbojas ar aukstu ultraska\u0146as (US) izsmidzin\u0101\u0161anu. Tom\u0113r BCP iztvaiko tikai no aptuveni 130 \u00b0C un sadeg temperat\u016br\u0101 virs 180 \u00b0C. \u0160\u0101 iemesla d\u0113\u013c j\u0101izmanto sild\u0101mi, temperat\u016bras kontrol\u0113ti difuzori (piem. <a href=\"https:\/\/storz-bickel.com\" target=\"_blank\" rel=\"noreferrer noopener\">Volcano Classic, Volcano Hybrid vai Mighty+<\/a>) cenu segment\u0101 no aptuveni 270 l\u012bdz 415 euro, un temperat\u016brai j\u0101b\u016bt iestat\u012btai p\u0113c iesp\u0113jas prec\u012bz\u0101k (p\u0101rbaudiet ar infrasarkano termometru) uz 160 \u00b0C.<\/p>\n\n\n\n<p>Ieteicam\u0101 deva Copaiba e\u013c\u013cai (doTERRA) ar 69 % BCP saturu - 1 piliens satur 18,6 mg BCP.<\/p>\n\n\n\n<p>BCP pusperiods ir 2-4 stundas. Lai sasniegtu p\u0113c iesp\u0113jas nemain\u012bg\u0101ku akt\u012bv\u0101s vielas l\u012bmeni, inhal\u0101cija j\u0101veic, k\u0101 aprakst\u012bts iepriek\u0161, ik p\u0113c 4 pilieniem (kas atbilst aptuveni 200 mg BCP) ik p\u0113c 4 stund\u0101m. Nakt\u012b net\u0101lu no gultas var atst\u0101t iesl\u0113gtu difuzoru.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Zieldosen_und_benotigte_Tropfenzahl\"><\/span>M\u0113r\u0137a devas un nepiecie\u0161amais pilienu skaits<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>M\u0113r\u0137a BCP deva<\/th><th>Kopaibas e\u013c\u013cas pilieni<\/th><th>Kop\u0113jais e\u013c\u013cas daudzums (mg)<\/th><\/tr><\/thead><tbody><tr><td>20 mg BCP (s\u0101kuma deva)<\/td><td><strong>~ 1 piliens<\/strong><\/td><td>~29 mg<\/td><\/tr><tr><td>50 mg BCP<\/td><td><strong>~3 pilieni<\/strong><\/td><td>~72 mg<\/td><\/tr><tr><td>100 mg BCP (terapeitiskais)<\/td><td><strong>~5-6 pilieni<\/strong><\/td><td>~145 mg<\/td><\/tr><tr><td>120 mg BCP (maksim\u0101l\u0101 dienas deva)<\/td><td><strong>~6-7 pilieni<\/strong><\/td><td>~ 174 mg<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>M\u0113r\u0137tiec\u012bgi inhal\u0113jams BCP<\/th><th>E\u013c\u013cas daudzums uz \u0161\u0137idr\u0101 spilventi\u0146a<\/th><th>Drops<\/th><\/tr><\/thead><tbody><tr><td>~20 mg BCP ieelpojot<\/td><td>~40 mg e\u013c\u013cas (~78 mg\/0,69)<\/td><td><strong>2-3 pilieni<\/strong><\/td><\/tr><tr><td>~ 50 mg BCP inhal\u0101cijas veid\u0101<\/td><td>~100 mg e\u013c\u013cas<\/td><td><strong>4-5 pilieni<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Synergistische_MOGAD-Strategie_Multi-Target\"><\/span>Siner\u0123iska MOGAD strat\u0113\u0123ija (vair\u0101ku m\u0113r\u0137u)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>T\u0101 k\u0101 MOGAD ir tr\u012bs patomeh\u0101nismi, \u0161\u012b uz pier\u0101d\u012bjumiem balst\u012bt\u0101 kombin\u0101cija rada:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Akt\u012bv\u0101 viela<\/th><th>Doz\u0113\u0161ana<\/th><th>Sign\u0101la ce\u013c\u0161<\/th><th>MOGAD noz\u012bme<\/th><\/tr><\/thead><tbody><tr><td><strong>BCP (iek\u0161\u0137\u012bgi)<\/strong><\/td><td>0,4-1,5 mg\/kg<\/td><td>CB2 \u2192 Th17\u2193, IL-6\u2193, Nrf2\/HO-1\u2191.<\/td><td>\u2605\u2605\u2605\u2605\u2605<\/td><\/tr><tr><td><strong>AKBA (mutiski)<\/strong><\/td><td>200-400 mg dien\u0101<\/td><td>STAT3\u2193, NF-\u03baB\u2193, 5-LOX\u2193.<\/td><td>\u2605\u2605\u2605\u2605\u2605<\/td><\/tr><tr><td><strong>BCP (ieelpojot, 160 \u00b0C)<\/strong><\/td><td>2-3 pilieni, 2\u00d7 dien\u0101<\/td><td>Limbiska, \u0101tra iek\u013c\u016b\u0161ana CNS<\/td><td>\u2605\u2605\u2605<\/td><\/tr><tr><td><strong>Smilts\u0113rk\u0161\u0137u e\u013c\u013ca (ieelpojot)<\/strong><\/td><td>3-4 pilieni, 2\u00d7 dien\u0101<\/td><td>Incensola acet\u0101ts \u2192 TRPV3, PPAR-\u03b3<\/td><td>\u2605\u2605\u2605<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>\u0160\u012b \u010detru p\u012bl\u0101ru strat\u0113\u0123ija risina \u0161\u0101dus jaut\u0101jumus:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Th17\/IL-6<\/strong> (BCP peror\u0101li + AKBA)<\/li>\n\n\n\n<li><strong>STAT3<\/strong> (AKBA)<\/li>\n\n\n\n<li><strong>Oligodendroc\u012btu aizsardz\u012bba<\/strong> (BCP Nrf2 aktiviz\u0113\u0161ana)<\/li>\n\n\n\n<li><strong>Limbisk\u0101 modul\u0101cija<\/strong> (ieelpojot)<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Wichtige_MOGAD-spezifische_Hinweise\"><\/span>Svar\u012bga MOGAD specifiska inform\u0101cija<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Nav monoterapijas<\/strong> - BCP\/AKBA ir <strong>Tradicion\u0101l\u0101s terapijas papildin\u0101jumi<\/strong><br>(kortizons ak\u016bti, nepiecie\u0161am\u012bbas gad\u012bjum\u0101 rituksimabs\/MMF\/IVIG profilaktiski) - nekad k\u0101 aizst\u0101j\u0113js.<\/li>\n\n\n\n<li><strong>Biomar\u0137ieru uzraudz\u012bba:<\/strong>\n<ul class=\"wp-block-list\">\n<li>MOG-IgG titrs ik p\u0113c 3-6 m\u0113ne\u0161iem<\/li>\n\n\n\n<li>sNfL (neirofilamentu gaisma) k\u0101 aktivit\u0101tes mar\u0137ieris<\/li>\n\n\n\n<li>Apsveriet devas samazin\u0101\u0161anu, ja titrs past\u0101v\u012bgi samazin\u0101s.<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Iev\u0113rojiet vilces ierosin\u0101t\u0101ju<\/strong> - Infekcijas ir galvenais ierosin\u0101t\u0101js<br>Infekcijas gad\u012bjum\u0101, ja nepiecie\u0161ams, ievadiet devu <strong>uz laiku palielina l\u012bdz 1,5 mg\/kg<\/strong> (prevent\u012bvs)<\/li>\n\n\n\n<li><strong>Copaiba aknu v\u0113rt\u012bbas<\/strong> - Ja &gt;1 mg\/kg &gt;3 m\u0113ne\u0161us<br>P\u0101rbaudiet ALT\/AST ik p\u0113c 3 m\u0113ne\u0161iem<\/li>\n\n\n\n<li><strong>Melno piparu alternat\u012bva<\/strong> - Attiec\u012bb\u0101 uz Copaiba: melno piparu e\u013c\u013ca (25-38 % BCP)<br>Tad apr\u0113\u0137ina pilienu skaitu \u00d7 2<\/li>\n<\/ol>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"%CE%B1-Asaron_Kalmus-Ol_Acorus_calamus_%E2%80%93_direkt_oligodendrozytenprotektiv\"><\/span>\u03b1-Asarons (kalmju e\u013c\u013ca, <em>Acorus calamus<\/em>) - tie\u0161i oligodendroc\u012btus aizsarg\u0101jo\u0161s l\u012bdzeklis<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Viena no nedaudzaj\u0101m akt\u012bvaj\u0101m sast\u0101vda\u013c\u0101m ar <strong>tie\u0161ais remieliniz\u0101cijas efekts<\/strong> ir . <em><strong><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37146420\/\" target=\"_blank\" rel=\"noreferrer noopener\">\u03b1-Asaron<\/a><\/strong><\/em>. Tas uzlabo dismieliniz\u0101ciju, ko izraisa nobriedu\u0161u oligodendroc\u012btu zudums p\u0113c hipoksijas i\u0161\u0113mijas, pateicoties PPAR-\u03b3 regul\u0101cijai un aktiviz\u0101cijai astroc\u012btos. Tas palielina glutam\u0101ta transportiera GLT-1 ekspresiju un no \u0101rpus\u0161\u016bnu telpas izvada p\u0101rm\u0113r\u012bgu glutam\u0101ta daudzumu, kas pret\u0113j\u0101 gad\u012bjum\u0101 OPC izrais\u012btu glutam\u0101ta izrais\u012btu eksitotoksicit\u0101ti, kav\u0113tu to diferenci\u0101ciju un izrais\u012btu \u0161\u016bnu n\u0101vi. <a href=\"https:\/\/www.klinikum.uni-heidelberg.de\/neurologische-klinik\/neurologie-und-poliklinik\/forschung\/neuroimmunology\/ag-molekulare-neuroimmunologie\/mog-enzephalomyelitis\" target=\"_blank\" rel=\"noreferrer noopener\">Heidelbergas Universit\u0101tes slimn\u012bca<\/a><\/p>\n\n\n\n<p>PPARy neirolo\u0123ij\u0101 - <a href=\"https:\/\/www.frontiersin.org\/journals\/neuroscience\/articles\/10.3389\/fnins.2022.1060515\/pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Frontiers Redakcija 2022<\/a><\/p>\n\n\n\n<p><strong>Uzman\u012bbu:<\/strong> Atkar\u012bb\u0101 no izcelsmes kalmju e\u013c\u013ca satur da\u017e\u0101dus \u03b2-asarona daudzumus, kas klasific\u0113ts k\u0101 mutag\u0113ns. Tikai <strong>\u03b2-Asaronu nesaturo\u0161as \u012bpa\u0161\u012bbas<\/strong> (Acorus calamus var. americanus).<\/p>\n\n\n\n<p><strong>Saska\u0146\u0101 ar pa\u0161reiz\u0113jo statusu (02.2026.) tirgus pieejam\u012bba nav nor\u0101d\u012bta.<\/strong><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Geraniumol_Pelargonium_graveolens_%E2%80%93_Neuroinflammation_und_NO\"><\/span>Ger\u0101niju e\u013c\u013ca (<em>Pelargonium graveolens<\/em>) - Neiroiekaisums un NO<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC7922935\/\" rel=\"nofollow noopener\" target=\"_blank\">Ger\u0101niju e\u013c\u013ca<\/a> var b\u016bt noder\u012bga neirode\u0123enerat\u012bvo slim\u012bbu gad\u012bjum\u0101, ja neiroinflammation ir da\u013ca no patofiziolo\u0123ijas.<br>Galven\u0101 akt\u012bv\u0101 viela <em>Citronelols<\/em> lielisku inhib\u0113jo\u0161u iedarb\u012bbu uz NO veido\u0161anos izr\u0101d\u012bja liel\u0101k\u0101s koncentr\u0101cij\u0101s, t\u0101p\u0113c noteico\u0161\u0101 noz\u012bme ir siner\u0123iskai mijiedarb\u012bbai starp sast\u0101vda\u013c\u0101m.<br>Citronelols ar\u012b inhib\u0113 NF-\u03baB, kas ir tie\u0161i saist\u012bts ar mikrogliju aktiv\u0101ciju MOGAD.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Teebaum-Ol_Melaleuca_alternifolia_%E2%80%93_Mikroglia-Modulation\"><\/span>T\u0113jas koka e\u013c\u013ca (<em>Melaleuca alternifolia<\/em>) - Mikroglijas modul\u0101cija<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10350368\/\" target=\"_blank\" rel=\"noreferrer noopener\">T\u0113jas koka e\u013c\u013ca<\/a> un t\u0101 galven\u0101s sast\u0101vda\u013cas inhib\u0113 AChE un BChE, k\u0101 ar\u012b LOX. Oksidat\u012bv\u0101 stresa optimiz\u0101cija, izmantojot antioksidantu \u012bpa\u0161\u012bbas, neiroinflammation inhib\u012bciju un AChE\/BChE inhib\u012bciju, var efekt\u012bvi veicin\u0101t neironu \u0161\u016bnu n\u0101ves nov\u0113r\u0161anu k\u0101 visp\u0101r\u0113ju strat\u0113\u0123iju.<br>Terp\u012bn\u0113n-4-ols (galven\u0101 akt\u012bv\u0101 viela) ar\u012b specifiski kav\u0113 mikroglia M1 polariz\u0101ciju.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Wirkstoffubersicht_nach_MOGAD-Signalwegen\"><\/span>Akt\u012bvo vielu p\u0101rskats saska\u0146\u0101 ar MOGAD signaliz\u0101cijas ce\u013ciem<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Akt\u012bv\u0101 viela<\/th><th>E\u013c\u013cas avots<\/th><th>MOGAD signaliz\u0101cijas ce\u013c\u0161<\/th><th>Pier\u0101d\u012bjumu pamatot\u012bba<\/th><\/tr><\/thead><tbody><tr><td><strong>\u03b2-kariofil\u0113ns (BCP)<\/strong><\/td><td>Melnie pipari, Copaiba<\/td><td>CB2 \u2192 Nrf2\/HO-1, PPAR-\u03b3; Th17\u2193, IL-6\u2193.<\/td><td>\u2605\u2605\u2605\u2605 (EAE modelis)<\/td><\/tr><tr><td><strong>AKBA<\/strong><\/td><td>Frankincense (<em>Boswellia serrata<\/em>)<\/td><td>STAT3\u2193, NF-\u03baB\u2193, 5-LOX\u2193, SPM\u2191, Nrf2\/HO-1\u2191.<\/td><td>\u2605\u2605\u2605\u2605 (CNS p\u0113t\u012bjumi)<\/td><\/tr><tr><td><strong>Incensola acet\u0101ts<\/strong><\/td><td>Frankincense (gaisto\u0161\u0101 da\u013ca)<\/td><td>TRPV3, PPAR-\u03b3, IL-6\u2193, GFAP\u2193<\/td><td>\u2605\u2605\u2605\u2605 (dz\u012bvnieku modelis)<\/td><\/tr><tr><td><strong>\u03b1-Asaron<\/strong><\/td><td>Kalamss (<em>Acorus calamus<\/em>)<\/td><td>PPAR-\u03b3 \u2192 GLT-1\u2191 \u2192 OPC aizsardz\u012bba, tie\u0161a remieliniz\u0101cija<\/td><td>\u2605\u2605\u2605\u2605 (hipoksijas modelis)<\/td><\/tr><tr><td><strong>Linalols<\/strong><\/td><td>Lavanda, citronmelisa<\/td><td>NMDA modul\u0101cija, SERT, neiroprotekcija<\/td><td>\u2605\u2605\u2605<\/td><\/tr><tr><td><strong>1,8-cineols<\/strong><\/td><td>Eikalipts, rozmar\u012bns<\/td><td>AChE inhib\u012bcija, antioksidants<\/td><td>\u2605\u2605\u2605\u2605 (pier\u0101d\u012bts smadzen\u0113s)<\/td><\/tr><tr><td><strong>Citronelols<\/strong><\/td><td>Ger\u0101nijs<\/td><td>NO\u2193, NF-\u03baB\u2193, siner\u0123ijas efekts<\/td><td>\u2605\u2605<\/td><\/tr><tr><td><strong>Terp\u012bn-4-ols<\/strong><\/td><td>T\u0113jas koks<\/td><td>Mikroglia M1\u2193, LOX\u2193, AChE\u2193<\/td><td>\u2605\u2605<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<div style=\"height:100px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Quellen_und_weiterfuhrende_Literatur\"><\/span><strong>Avoti un turpm\u0101k\u0101 las\u0101mviela<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Banwell B et al - Lancet Neurol. 2023;22:268-282<\/strong> Diagnostikas krit\u0113riji MOGAD<br><strong>PubMed (bez maksas):<\/strong> <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36706773\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/36706773\/<\/a> <br><strong>ScienceDirect (abstrakts bez maksas, pilnais teksts ar izmaks\u0101m):<\/strong> <a href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S1474442222004318\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S1474442222004318<\/a> <br><strong>DOI:<\/strong> <a href=\"https:\/\/doi.org\/10.1016\/S1474-4422(22)00431-8\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/doi.org\/10.1016\/S1474-4422(22)00431-8<\/a><\/li>\n\n\n\n<li><strong>Mader S et al - PNAS 2023<\/strong> <em>(Piez\u012bme: m\u016bsu dokument\u0101 min\u0113ta k\u0101 \u201ePNAS 2024\" - pareizais public\u0113\u0161anas gads ir 2023. gada marts)<\/em> Komplementa vs. FcR patomeh\u0101nisms, LMU Minhene<br><strong>PNAS pilnais teksts (bezmaksas):<\/strong> <a href=\"https:\/\/www.pnas.org\/doi\/10.1073\/pnas.2300648120\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.pnas.org\/doi\/10.1073\/pnas.2300648120<\/a> <br><strong>LMU pazi\u0146ojums presei (ar paskaidrojumu):<\/strong> <a href=\"https:\/\/www.med.lmu.de\/bmc\/en\/news\/latest-news\/news-overview\/news\/autoimmune-disease-mogad-insights-into-pathomechanisms.html\" target=\"_blank\" rel=\"noopener\">https:\/\/www.med.lmu.de\/bmc\/en\/news\/latest-news\/news-overview\/news\/autoimmune-disease-mogad-insights-into-pathomechanisms.html<\/a> <br><strong>EAN koment\u0101ri:<\/strong> <a href=\"https:\/\/www.ean.org\/research\/resources\/neurology-updates\/detail\/complement-dependent-and-independent-pathomechanisms-of-myelin-oligodendrocyte-glycoprotein-mog-abs-implications-for-therapeutic-strategies-in-mog-antibody-associated-disease-mogad\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.ean.org\/research\/resources\/neurology-updates\/detail\/complement-dependent-and-independent-pathomechanisms-of-myelin-oligodendrocyte-glycoprotein-mog-abs-implications-for-therapeutic-strategies-in-mog-antibody-associated-disease-mogad<\/a> <\/li>\n\n\n\n<li><strong>Kaneko K et al - Neurol Neuroimmunol Neuroinflamm. 2024;11(5):e200293<\/strong> CSF komplementa aktiv\u0101cija<br>Raksts e200293 ir <strong>nevar atrast tie\u0161i<\/strong> - Tom\u0113r ir pieejams saist\u012btais MOGAD p\u0101rskata raksts no t\u0101 pa\u0161a izdevuma (e200275, Moseley\/Zamvil):<br><strong>Neirolo\u0123ija NXI (e200275, tas pats izdevums):<\/strong> <a href=\"https:\/\/www.neurology.org\/doi\/10.1212\/NXI.0000000000200275\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.neurology.org\/doi\/10.1212\/NXI.0000000000200275<\/a> <br><strong>PubMed mekl\u0113t Kaneko 2024 MOGAD CSF:<\/strong> <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/38996203\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/38996203\/<\/a> <em>(ved uz e200275 - ieteicama tie\u0161a mekl\u0113\u0161ana PubMed p\u0113c e200293)<\/em><\/li>\n\n\n\n<li><strong>Cho EB et al - Front Immunol. 2024;15:1320094<\/strong> Papildino\u0161s modelis MOGAD pret NMOSD<br><strong>Frontiers (pilnais teksts bez maksas):<\/strong> <a href=\"https:\/\/doi.org\/10.3389\/fimmu.2024.1320094\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/doi.org\/10.3389\/fimmu.2024.1320094<\/a> <em>(DOI ir tie\u0161i pieejams)<\/em><\/li>\n\n\n\n<li><strong>Frontiers Immunol. 2025 - EAE mode\u013ci, MOGAD pato\u0123en\u0113ze<\/strong> <em>(Dokument\u0101 parasti ir atsauce uz p\u0101rskata rakstu par signaliz\u0101cijas ce\u013ciem\/patomeh\u0101nismiem).<\/em><br><strong>Frontiers Immunol. 2025 (Sun et al., PMID 40406135):<\/strong> <a href=\"https:\/\/doi.org\/10.3389\/fimmu.2025.1535571\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/doi.org\/10.3389\/fimmu.2025.1535571<\/a><\/li>\n\n\n\n<li><strong>PMC 2023 - Visaptvero\u0161s p\u0101rskats Patofiziolo\u0123ija MOGAD<\/strong><br><strong>PMC Pilnais teksts (bezmaksas):<\/strong> <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9597055\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9597055\/<\/a><\/li>\n\n\n\n<li><strong>PMC 2024 - Atjaunin\u0101ts p\u0101rskats Kl\u012bnisk\u0101 spektra, pato\u0123en\u0113zes, \u0101rst\u0113\u0161anas apraksts<\/strong><br><strong>PubMed\/PMC (Trewin et al., Autoimmun Rev 2025):<\/strong> <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/39577549\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/39577549\/<\/a><br><strong>PMC pilnais teksts:<\/strong> <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9294102\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9294102\/<\/a> <em>(Monoklon\u0101lo antivielu terapija NMOSD\/MOGAD)<\/em><\/li>\n\n\n\n<li><strong>St\u00f6gbauer J et al - Autoimmunity Reviews 2025;103970<\/strong> Terapeitisk\u0101s pieejas Pieaugu\u0161ie MOGAD<br><strong>ScienceDirect (atkl\u0101t\u0101 piek\u013cuve, bezmaksas pilnais teksts):<\/strong> <a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1568997225002319\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1568997225002319<\/a> <br><strong>DOI:<\/strong> <a href=\"https:\/\/doi.org\/10.1016\/j.autrev.2025.103970\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/doi.org\/10.1016\/j.autrev.2025.103970<\/a> <br><strong>Kopsavilkums v\u0101cu valod\u0101:<\/strong> <a href=\"https:\/\/www.reine-nervensache.de\/therapieansaetze-bei-mogad-von-der-akutbehandlung-zur-langfristigen-strategie\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.reine-nervensache.de\/therapieansaetze-bei-mogad-von-der-akutbehandlung-zur-langfristigen-strategie\/<\/a> <\/li>\n\n\n\n<li><strong>Ekspertu atzinums par jaun\u0101m z\u0101l\u0113m 2025 - kl\u012bnisko p\u0113t\u012bjumu ainava<\/strong><br><strong>Tandfonline (abstrakts bez maksas, pilns teksts ar izmaks\u0101m):<\/strong> <a href=\"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14728214.2025.2565189\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14728214.2025.2565189<\/a><br><strong>DOI:<\/strong> <a href=\"https:\/\/doi.org\/10.1080\/14728214.2025.2565189\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/doi.org\/10.1080\/14728214.2025.2565189<\/a><br><\/li>\n\n\n\n<li><strong>NEMOS izp\u0113tes grupa<\/strong> <a href=\"https:\/\/www.nemos-net.de\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.nemos-net.de<\/a><br><\/li>\n\n\n\n<li><strong>Uz pacientu orient\u0113ta p\u0113t\u012bjuma p\u0101rskats (cosMOG\/METEOROID):<\/strong><br>MOG projekts - <a href=\"https:\/\/mogproject.org\/clinical-trials\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/mogproject.org\/clinical-trials\/<\/a><br>ClinicalTrials.gov - cosMOG - <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05063162\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/clinicaltrials.gov\/study\/NCT05063162<\/a><\/li>\n<\/ul>\n\n\n\n<div style=\"height:100px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>Viss saturs ir r\u016bp\u012bgi izp\u0113t\u012bts un atspogu\u013co pa\u0161reiz\u0113jo (02.2026.) public\u0113to zin\u0101\u0161anu l\u012bmeni. Tas ir paredz\u0113ts tikai informat\u012bviem nol\u016bkiem un neaizst\u0101j profesion\u0101lu \u0101rsta konsult\u0101ciju.<br>Visi devu ieteikumi j\u0101saska\u0146o ar \u0101rst\u0113jo\u0161o \u0101rstu. <br>Saist\u012btie p\u0113t\u012bjumi sniedz \u0101rstam papildu medic\u012bnisko un zin\u0101tnisko inform\u0101ciju.<\/p>\n<\/blockquote>","protected":false},"excerpt":{"rendered":"<p><span class=\"span-reading-time rt-reading-time\" style=\"display: block;\"><span class=\"rt-label rt-prefix\">Las\u012b\u0161anas laiks<\/span> <span class=\"rt-time\"> 17<\/span> <span class=\"rt-label rt-postfix\">protokols<\/span><\/span>Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease Was ist MOGAD? Jeder kennt elektrische Leitungen: Sie sind mit einer Isolierung versehen, die die einzelne Leiter im Kableb\u00fcndel von einander trennt, damit die Signale in ihnen einander nicht st\u00f6ren und unverf\u00e4lscht von A nach B gelangen.Das R\u00fcckenmark beinhaltet einen ganzen Strang vieler solcher Kabelb\u00fcndel. Sie leiten die Nervensignale vom&hellip;&nbsp;<a href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/\" rel=\"bookmark\">Las\u012bt vair\u0101k \"<span class=\"screen-reader-text\">MOGAD - ar MOG antivielu saist\u012bta slim\u012bba<\/span><\/a><\/p>","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","neve_meta_sidebar":"","neve_meta_container":"","neve_meta_enable_content_width":"","neve_meta_content_width":0,"neve_meta_title_alignment":"","neve_meta_author_avatar":"","neve_post_elements_order":"","neve_meta_disable_header":"","neve_meta_disable_footer":"","neve_meta_disable_title":"","footnotes":""},"categories":[1078,354],"tags":[94,5721,5717,5720,5714,5713,5711,5715,5719,5716,77,90,5712,5718],"class_list":["post-12718","post","type-post","status-publish","format-standard","hentry","category-medizin","category-medizin-gesundheit","tag-antikoerper","tag-bcp","tag-glykoprotein","tag-igg","tag-mog","tag-mogad","tag-molekulare-signalwege","tag-myelin","tag-myelinscheide","tag-oligodendrozyten","tag-pathophysiologie","tag-rezeptoren","tag-therapiekonzepte","tag-transmebranprotein"],"modified_by":"Achim Goerner","_links":{"self":[{"href":"https:\/\/csiag.eu\/lv\/wp-json\/wp\/v2\/posts\/12718","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/csiag.eu\/lv\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/csiag.eu\/lv\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/csiag.eu\/lv\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/csiag.eu\/lv\/wp-json\/wp\/v2\/comments?post=12718"}],"version-history":[{"count":0,"href":"https:\/\/csiag.eu\/lv\/wp-json\/wp\/v2\/posts\/12718\/revisions"}],"wp:attachment":[{"href":"https:\/\/csiag.eu\/lv\/wp-json\/wp\/v2\/media?parent=12718"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/csiag.eu\/lv\/wp-json\/wp\/v2\/categories?post=12718"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/csiag.eu\/lv\/wp-json\/wp\/v2\/tags?post=12718"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}